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Binski: Balancing Policy Tensions of the Vaccine Act in Light of the Omni

NOTE
BALANCING POLICY TENSIONS OF THE
VACCINE ACT IN LIGHT OF THE OMNIBUS
AUTISM PROCEEDING: ARE PETITIONERS
GETTING A FAIR SHOT AT COMPENSATION?
I.

INTRODUCTION

Her life has been marked with sadness and suffering, but when
Michelle Cedillo was born in 1994 she was a happy, healthy baby.' She
shifted into her toddler years meeting all key developmental milestones. 2
Then at fifteen months of age she received the measles-mumps-rubella
("MMR") vaccine3 and her life was changed forever. Michelle's
development began to regress as she became increasingly less interactive
and affectionate, lost motor skills and the ability to verbalize, and began
engaging in repetitive behavior patterns.4 Her condition continued to
1. Theresa Cedillo, Gone in Seven Days: A Brief Story of Our DaughterMichelle's Vaccine
Injury and Subsequent Landmark Court Case, 33 THE AUTISM FILE 46, 46 (2009).
2. See Cedillo, supra note 1, at 46; Learn the Signs - Milestones, AUTISM SPEAKS, http://
www.autismspeaks.org/whatisit/milestones.php (last visited July 4, 2011) (describing typical
developmental milestones for children. For example, a child at three to four months of age
"[w]atches faces with interest and follows moving objects ... [b]egins to develop a social smile[,
and] [tiums [her] head toward sounds." At seven months, a child typically "[r]esponds to other
people's emotions[,] [e]njoys face-to-face play . .. [and] [r]esponds to [her] own name." A one-year
old child generally "[e]njoys imitating people; tries to imitate sounds . .. uses simple gestures[] such
as pointing to an object, [and] [b]abbles with changes in tone[] [or] may use single words." By two
years of age, a child "[u]nderstands several words[,] ... [b]egins to sort by shapes and colors
[and] ... [c]ombines two words to communicate with others." At three years old, a child
"[e]xpresses affection openly and has a wide range of emotions[,] ... [flollows a 2- or 3- part
command[,] [and] uses simple phrases to communicate with others.").
3. Cedillo, supra note 1, at 46; see also Michael E. Horwin, Comment, Ensuring Safe,
Effective and Necessary Vaccines for Children, 37 CAL. W. L. REV. 321, 326 (2001) (noting that
children today receive twenty-four injections, including "five doses of DPT, four doses of polio
vaccine, two doses of measles, mumps and rubella, three injections of hepatitis B, one shot of
varicella (chicken pox), .... four injections of a pneumococcal conjugate vaccine, and, depending on
where the child lives, . . . one shot of hepatitis A"). In addition, twenty of these injections are
administered before the child reaches eighteen months old. Id
4. See Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009 at 20, Cedillo v. Sec'y of HHS, 89 Fed. Cl. 158 (2009) (No. 98916V), available at http://www.whale.to/vaccine/michellesappeal03162009.pdf ("Mr. and Mrs.
Cedillo noticed a change in Michelle's behavior beginning a few weeks after her illness following
the MMR vaccination. Michelle became less interactive and affectionate with her family, and
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decline, and, eventually Michelle was diagnosed with autism. 5
Michelle, now a teenager, spends most of her life confined to her
bed or a wheelchair instead of attending football games and dances with
friends.6 In addition, she is under the care of seven pediatric specialists,
must use a feeding tube for meals and medication, cannot speak, and
requires constant supervision from her parents.7 Unfortunately,
Michelle's story is not unique. Michelle Cedillo is just one of thousands
of children who allege that the administration of a childhood vaccine
caused them to develop autism.
Autism is loosely defined as a complex and life-long neurological
disorder.9 Although the modem study of autism began in 1943 by the
Austrian psychiatrist Leo Kanner,'o there is still little known about the
condition's exact etiology." Characterized as a developmental disorder,
autism typically manifests during early childhood and adversely affects
the individual's ability to develop normally.12 The symptoms of autism
range from mild to severe brain dysfunction that may cause impairments
in verbal and physical communication, difficulty with social interaction,
and decreased physical health.13 These symptoms serve to isolate the
autistic from the world around them and cause numerous hardships for
stopped using words and communicative behavior she previously produced.").
5. Cedillo, supra note 1, at 46. "Autism is a complex developmental disability that typically
appears during the first three years of life and affects a person's ability to communicate and interact
with others. Autism is defined by a certain set of behaviors and is a 'spectrum disorder' that affects
individuals differently and to varying degrees." About Autism, AUTISM SOC'Y, http://www.autismsociety.oTg/about-autism/ (last updated Jan. 21, 2008).
6. See Cedillo, supranote 1, at 47.
7. Id. at 46. In addition to autism, Michelle suffers from "Crohn's disease, arthritis,
spondyloarthritis, osteoporosis, uveitis, open angle glaucoma, and intractable grand mal epilepsy."
Id
8. As of August 2010, over 5,600 petitions for compensation have been filed alleging that
certain childhood vaccines caused or contributed to autism. Dep't of Health & Human Servs., About
the Omnibus Autism Proceeding, HEALTH RESOURCES & SERV. ADMIN., http://www.hrsa.gov/

vaccinecompensation/omnibusproceeding.htm (last updated Dec. 21, 2010) [hereinafter Omnibus
Autism Proceeding].
9. Helia Garrido Hull, Induced Autism: The Legal and Ethical Implications of Inoculating
Vaccine Manufacturersfrom Liability, 34 CAP. U. L. REv. 1, 4 (2005).
10. See generally Leo Kanner, Autistic DisturbancesofAffective Contact, 2 NERV. CHILD 217
(1943) (describing Kanner's breakthrough observations and evaluations on the behavior of eleven
autistic children).
11. Hull, supra note 9, at 3-4.
12. Katherine Marie Bulfer, Childhood Vaccines and Autism: Does the National Childhood
Vaccine Injury Act Leave Parentsof Children with Autism Out in the Cold with Nowhere to Go?, 27
CAMPBELL L. REv. 91, 92 (2004).
13. Hull, supra note 9, at 4; Joelle Anne Moreno, It's Just a Shot Away: MMR Vaccines and
Autism and the End of the DaubertistaRevolution, 35 WM. MITCHELL L. REv. 1511, 1518 (2009);
see also Cedillo, supra note 1, at 46 (discussing the decline in physical health for a recently
diagnosed autism patient).
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their caretakers.14 Although autism generally affects an individual for her
entire life, the condition generally has no effect on the individual's life
span.is
Documented cases of autism around the world have experienced a
marked increase in recent history.16 In fact, the most recent data from the
Centers for Disease Control suggests that one in every 110 children in
the United States is diagnosed with an autism spectrum disorder
("ASD").17 That figure represents a huge increase from studies
conducted in the 1960s that indicated only four or five cases of autism in
every 10,000 people.' 8 The growing prevalence of the disorder has led
many researchers and advocacy groups to refer to the increase as the
"autism 'epidemic.'"
Several theories are posited to explain the rise in instances of
autism.20 Some researchers contend that the escalation in cases does not
represent a true increase but is instead a reflection of the broadened
definition of ASD and heightened recognition of autism. 2' Still others
believe that autism is created by certain "[g]enetic predisposition[s],
metabolic abnormalities, and abnormalities of the gastrointestinal,
hepatic, [or] immune system[] .22 Advocates of the theory linking autism
to vaccines assert that vaccines can either exacerbate the above
abnormalities and ultimately result in autism, or that vaccines can cause
autism independent of other preexisting factors. 2 3
14. Bulfer, supra note 12, at 92-93 (noting that in addition to the characteristic difficulties of
physical and verbal communication, some individuals with autism never learn to speak).
15. Holly Bortfeld, Health Insurance Coverage for Biomedical & Traditional Treatments,
TALK ABOUT CURING AUTISM (Sept. 1, 2008), http://www.talkaboutcuringautism.org/resources/
autism-insurance/insurance-coverage-for-biomedical-traditional-treatments.htm.
16. See Hull, supranote 9, at 4-5 (discussing the prevalence of autism).
17. Ctrs. for Disease Control & Prevention, Prevalence of Autism Spectrum Disorders Autism and Developmental DisabilitiesMonitoring Network, United States, 2006, 58 MORBIDITY &
MORTALITY WKLY. REP. 1, 14 (2009), available at http://www.cdc.gov/mmwr/pdf/ss/ss5810.pdf
[hereinafter Prevalenceof Autism Spectrum Disorders].Autism spectrum disorders ("ASD") are a
range of developmental disorders "characterized by atypical development in socialization,
communication, and behavior." Id. at 2. See also Bradley J. Andrus, In the Courts: Autism
Proceedingsin the Vaccine Court, 28 CHILD. LEGAL RTS. J. 56, 57 (2008) (explaining that the three
main types of ASD are autism, Asperger's syndrome, and Pervasive Developmental Disorder Not
Otherwise Specified (PDD-NOS)).
18. Bulfer, supra note 12, at 93.
19. Id; Jeffrey P. Baker, Mercury, Vaccines, and Autism: One Controversy, Three Histories,
98 AM. J. PUB. HEALTH 244, 250 (2008).
20. See Andrus, supra note 17, at 60; Bulfer, supra note 12, at 93-94; Moreno, supra note 13,
at 1520-21.
21. Moreno, supra note 13, at 1519.
22. Bulfer, supra note 12, at 93.
23. See The Autism Proceedings: Background Information, U.S. CT. OF FED. CLAIMs, http://
www.uscfc.uscourts.gov/sites/default/files/autism.background.2010_0.pdf (last updated Mar. 12,
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Over the past decade, the fear of a causal link between vaccines and
autism has garnered an anti-vaccination movement comprised of a large
group of skeptics who maintain that vaccines are dangerous and should
not be used.24 Though it was already years in the making, the vaccineautism controversy really began to heat up in 1998 when a study
published in the Lance 5 by British doctor Andrew Wakefield 2 6
indicated a link between the MMR vaccine and autism. 2 7 Then in 1999,
the U.S. Public Health Service and the American Academy of Pediatrics
recommended that vaccine manufacturers remove thimerosal 28 from
vaccines as soon as possible. 2 9 Finally, in 2008, the U.S. Department of
Health and Human Services conceded that a vaccine had irritated a
preexisting mitochondrial condition in ten-year old Hannah Poling that

2010 1:38PM) (listing the three theories of general causation under which autism petitions have
been filed).
24. Chris Mooney, Why Does the Vaccine/Autism Controversy Live On?, DISCOVER, June
2009, at 58, 59 ("The idea that there is something wrong with our vaccines-that they have
poisoned a generation of kids, driving an 'epidemic' of autism-continues to be everywhere: on
cable news, in celebrity magazines, on blogs, and in health news stories. It has had a particularly
strong life on the Internet, including the heavily trafficked Huffington Post, and in pop
culture ... [d]espite repeated rejection by the scientific community, it has spawned a movement, led
to thousands of legal claims, and even triggered occasional harassment and threats against scientists
whose research appears to discredit it.").
25. See A.J. Wakefield et al., Ileal-Lymphoid-Nodular Hyperplasia, Non-Specific Colitis, and
Pervasive Developmental Disorder in Children, 351 LANCET 637 (1998). It should be noted that this
article was later retracted because "it has become clear that several elements . . . are incorrect, [and]
contrary to the findings of an earlier investigation." Editors of the Lancet, Retraction-Ileallymphoid-nodular Hyperplasia, Non-specific Colitis, and Pervasive Developmental Disorder in
Children (Feb. 2, 2010), http://press.thelancet.com/wakefieldretraction.pdf
26. Andrew Wakefield, a British former gastrointestinal surgeon, was the lead author of the
controversial 1998 article first linking vaccines to autism. See Profile: Andrew Wakefield, the Man
at the Centre of the MMR Scare, THE TIMES (May 24, 2010), http://www.timesonline.co.uk/
tol/news/uk/article7l35099.ece. Dr. Wakefield's findings resulted in a frenzied fear of vaccines,
causing immunization levels to plunge to record lows. Id. In the aftermath of the article, Dr.
Wakefield was accused of fraud and his study was eventually discredited. Id In 2010, Dr.
Wakefield's British medical license was revoked. Id He currently lives in Texas where he continues
to research autism. Id.
27. See generally Wakefield et al., supra note 25 (describing a study of twelve previously
normal autistic children who had developed inflammatory bowel disease after receipt of the MMR
vaccine); but see Kevin B. O'Reilly, Regaining Trust Afler Vaccine Threat Debunked, AM. MED.
NEWS (Jan. 24, 2011), http://www.ama-assn.orglamednews/2011/01/24/prl20124.htm (noting that
the Lancet retracted Dr. Wakefield's article in January 2010. In addition, Dr. Wakefield's study has
been met with countless allegations of fraud, conflicts of interest, and ethics violations after the
British Medical Journal concluded that Wakefield had "'altered numerous facts about the patients'
medical histories in order to support his claim to have identified a new syndrome' and 'sought to
exploit the ensuing MMR scare for financial gain."').
28. Andrus, supra note 17, at 57. Thimerosal is a preservative composed of 49.6% ethyl
mercury by weight that was used in over thirty childhood vaccines before it was completely phased
out in 2001. Id. at 57; Moreno, supra note 13, at 1514 n.13.
29. Andrus, supra note 17, at 57.
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resulted in her developing autism. 3 0 Although research is ongoing,
numerous medical and scientific reports, as well as the U.S. Court of
Appeals for the Federal Circuit, expressly deny a vaccine-autism link.
In 1986, Congress established the Vaccine Injury Compensation
Program ("VICP") to guarantee the continued stability of the vaccine
market and to ensure compensation for individuals who had been injured
by a vaccine.32 Vaccine injury claims are overseen by the Office of
Special Masters ("OSM") of the Court of Federal Claims,33 informally
referred to as "Vaccine Court." 34 In 2002, as a response to the growing
vaccine-autism controversy, the OSM coordinated the "'Omnibus
Autism Proceeding"' ("OAP")3 5 to consolidate and adjudicate the
significant number of anticipated claims alleging a causal relationship
between vaccines and autism. 6
The OAP is significant for several reasons. For one, there are
currently 5636 petitioners in the OAP searching for answers to their
illness and anxiously waiting to find out whether they will receive

30. See Poling ex rel. Poling v. Sec'y of HHS, No. 02-1466V, 2008 WL 1883059, at *3 (Fed.
Cl. Apr. 10, 2008); Michael J. Donovan, The Impact of "Hurricane" Hannah: The Government's
Decision to Compensate in One Girl's Vaccine Injury Case Could DrasticallyAlter the Face of
Public Health, 50 JURIMETRICS J. 229, 233, 249 (2010) (describing the government's decision to
award compensation to Hannah Poling despite the fact that causation was not demonstrated and
noting that no rationale has been published for the Court's conclusion).
31. See, e.g., Cedillo v. Sec'y of HHS, 617 F.3d 1328, 1337 (Fed. Cir. 2010); Hazlehurst v.
Sec'y of HHS, 604 F.3d 1343, 1354 (Fed. Cir. 2010); Snyder ex rel. Snyder v. Sec'y of HHS, 88
Fed. Cl. 706, 748 (2009); IMMUNIZATION SAFETY REVIEW COMM. BD. ON HEALTH PROMOTION &
DISEASE PREVENTION, IMMUNIZATION SAFETY REVIEW: VACCINES AND AUTISM 7 (2004) (detailing

a 2004 study conducted by the Institute of Medicine (IOM) that conclusively rejects a causal
relationship between vaccines and autism). There has also been an inability to recreate the initial
findings of Dr. Wakefield's study, leading to numerous retractions on the part of Dr. Wakefield and
criticisms of his study. See Mady Hornig et al., Lack ofAssociation Between Measles Virus Vaccine
and Autism with Enteropathy: A Case-ControlStudy, PLOS ONE, Sept. 2008, at 1, 5, available at
http://www.plosone.org/article/info:doi/10. 137 1/joumal.pone.0003140.
32. See National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755
(1986) (codified at 42 U.S.C. § 300aa-1-34 (2006)). The compensation provision is located at
§ 330aa-10(a) of the Act. 42 U.S.C. § 300aa-10(a) (2006).
33. Vaccine injury claims are governed under the National Childhood Vaccine Injury
Compensation Act ("Vaccine Act" or "Act"). 42 U.S.C. § 300aa-10- 1l (2006). The Act further
establishes the Office of Special Masters. 42 U.S.C. § 300aa-12(c)(1) (2006).
34. The mainstream media commonly refers to the OSM as the "Vaccine Court." See, e.g.,
Miranda Hitti, Vaccine Court Rejects Autism Claims, WEBMD (Feb. 12, 2009), http://www.
webmd.com/brain/autism/news/20090212/vaccine-court-rejects-autismelaims.
35. See Autism General Order# 1, 2002 WL 31696785, at *3 (Fed. Cl. July 3, 2002).
36. Id. at *1. The OAP adopted a two-step procedure for handling autism claims. First, the
OSM designated eight individual special masters to explore into the general causation issues
involved in the case (specifically, whether there exists a causal link between vaccines and autism).
In the second step of the framework, the designated special masters were to apply the findings of the
general causation inquiry to the individual cases. Id. at *3.
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compensation.3 7 In addition, the claims of a vaccine-autism link have
created tremendous anxiety in the hearts and minds of many parents who
struggle with the question of whether they should have their children
vaccinated. Vaccine proponents who emphasize the health benefits of
vaccines are optimistic that the OAP will reassure worried parents by
conclusively establishing that there is no link between vaccines and
autism.39
The OAP is also significant for revealing the fundamentally
competing policy tensions that exist between compensating injured
petitioners and upholding the public confidence in vaccines and their
use. 40 This Note contends that these unresolved policy conflicts have
created a tension that burdens special masters during the fact-finding
process. The high-publicity case Cedillo v. Secretary of Health and
Human Services4 1 will be applied as an example of how the tension
special masters feel may influence their ultimate conclusions. Although
it will highlight scientific evidence from Cedillo and analyze the Special
Master's findings, this Note is not an attempt to draw any conclusions
regarding the safety of vaccines or the existence of a vaccine-autism
link.
This Note will proceed as follows. Part II will review the general
history of vaccines, the current use of vaccines in the United States, and
the events immediately preceding the creation of the Vaccine Act. The
discussion will then shift to a detailed description of the Vaccine Act's
statutory framework and relevant Vaccine Court precedent. This Part
will conclude by tracing the formation of the OAP and providing a brief
account of the OAP test case Cedillo.
Part III will commence with an outline of the legislative intent of
the Vaccine Act and the emergence of the competing policy concern.
Next, this Part will articulate how the task of balancing the incompatible
policies has fallen on the shoulders of the special masters rather than
being resolved by Congress or the Federal Circuit. Part III will also

37. Dep't of Health & Human Servs., National Vaccine Injury Compensation Program:
Statistics Report, HEALTH RESOURCES & SERV. ADMIN. (June 2, 2011), http://www.hrsa.gov/
vaccinecompensation/statistics-report.htm [hereinafter VICP Statistics Report].
38. Erin Andersen, ParentsRemain Skeptical Over Newest Autism Report, LINCOLN J. STAR
(Jan. 8, 2011, 6:00 AM), http://joumalstar.com/news/local/article_91aae8b3-82d9-5716-ac5c3c4a4bbc7000.html; see also Roy Richard Grinker, Op-Ed., Science on Trial, WALL ST. J., June 30July 1, 2007, at A6 (noting that the "anti-vaccine movement may be evidence that the public
confidence in science is eroding, which means that public health is at risk too").
39. See Arthur Allen, In Your Eye, Jenny McCarthy:A Special Court Rejects Autism-Vaccine
Theories, SLATE (Feb. 12, 2009, 3:35 PM ET), http://www.slate.com/id/2211156.
40. See discussion infra Part m.A-B.
41. 617 F.3d 1328 (Fed. Cir. 2010).

http://scholarlycommons.law.hofstra.edu/hlr/vol39/iss3/6

6

Binski: Balancing Policy Tensions of the Vaccine Act in Light of the Omni

BALANCING POLICY TENSIONS OF THE VACCINE ACT

2011]

689

examine the impact and consequences that the conflicting policy
concerns may have on the OAP. Part IV will provide a detailed
illustration of how Cedillo highlights the issue of fundamental policy
clashes and how special masters have been left to strike the balance
between them.
Part V proposes a process solution to improve the OAP cases to
ensure that the original intent of Congress is upheld. Specifically, Part V
will recommend that the Federal Circuit give more guidance to the
special masters on how to strike a balance between the competing
policies. Finally, this Part will conclude with a discussion of how
clarifying previous Federal Circuit precedent and providing more
guidance will be the fairest and most efficient way to balance the policy
tensions.
II.

FROM SHARP POINTS TO PUNCTURE WOUNDS: THE IMPACT OF
VACCINES AND THEIR USE IN THE PAST, PRESENT, AND FUTURE

Vaccines are commonly celebrated as a great victory for modem
medicine and public health. 42 The use of vaccines has been instrumental
in the near to complete eradication of diseases which have historically
claimed millions of lives. 43 Today, vaccines are considered to be so
effective that every state has made immunization a condition precedent
to enrollment in public or private school or licensed day care facilities.4
Several vaccines are presently mandated in the United States to prevent
diseases such as "polio, diphtheria, pertussis, tetanus, measles, mumps,
rubella, congenital rubella syndrome, smallpox, influenza, hepatitis B,

42. Ctrs. for Disease Control & Prevention, Ten Great Public Health Achievements-United
States, 1900-1999, 48 MORBIDITY & MORTALITY WKLY. REP. 241, 247 (1999), available at
http://www.cdc.gov/mmwr/preview/mnimwrhtml/00056803.htm [hereinafter Ten Great Public Health
Achievements]; see also H.R. REP. No. 99-908, at 4 (1986), reprinted in 1986 U.S.C.C.A.N. 6344,
6345 (stating that "(v]accination of children against deadly, disabling, but preventable infectious
diseases has been one of the most spectacularly effective public health initiatives this country has
ever undertaken").
43. See Ten Great Public Health Achievements, supra note 42, at 243-44 (explaining that
prior to the advent of vaccines, diseases and viruses such as smallpox, polio, diphtheria, measles,
mumps, and rubella were rampant); Rob Henson, Comment, Inoculated Against Recovery: A
ComparativeAnalysis of Vaccine Injury Compensationin the United States and Great Britain, 15
TULSA J. COMP. & INT'L L. 61, 61 (2007) (noting that at the dawn of the twentieth century,
infectious disease was so prevalent that 160 of every 1000 children born in the United States never
reached their fifth birthday).
44. See James G. Hodge, Jr. & Lawrence 0. Gostin, School Vaccination Requirements:
Historical, Social, and Legal Perspectives, 90 KY. L.J. 831, 868-69 (2002) (noting that most
existing vaccination laws were enacted as a precautionary measure in response to the measles
outbreak in schools during the 1960s and 1970s).
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varicella (chicken pox), Haemophilus influenzae type b.. ., and
pneumococcal disease.'
A.

Vaccines: Past andPresent

The science behind vaccines is groundbreaking and dates back to
the ancient Indian practice of "variolation," or direct, intentional
exposure to a virus in order to create immunity. 4 6 A contemporary
vaccination is essentially the introduction of a weakened strain of a
particular disease or virus into the body in order to create antibodies.47
The weakened strain of antigens is typically not strong enough to create
full-blown symptoms of the virus or disease but is strong enough for the
immune system to create antibodies against them.48 In turn, these
antibodies respond by attacking and defeating the intruding organism
that was introduced into the body by the vaccine. 49 The cells involved in
the antibody production create "memory cells" to remember the antigen
and defend the body if it encounters the virus or disease again.so
In 1796, Dr. Edward Jenner created the first contemporary
vaccine.5 Dr. Jenner obtained cowpox matter from the arm of a
dairymaid who was previously infected with smallpox and introduced
the sample into the arm of a healthy young boy.5 2 The boy became
immune to smallpox, and modern vaccines were born. Dr. Jenner's
discovery marked the beginning of the recognition that introducing a
weakened strain of a virus (rather than a full-blown attack as in
variolation) was a much safer and effective approach to creating mass

immunity.54

45. Henson, supra note 43, at 61.
46. See Steve P. Calandrillo, Vanishing Vaccinations: Why Are So Many Americans Opting
Out of Vaccinating Their Children?, 37 U. MIcH. J.L. REFORM 353, 363 (2004) (explaining
variolation and how the theories supporting it eventually led to the creation of contemporary
vaccines).
47. Id. at 362-63.
48. Ctrs. for Disease Control & Prevention, How Vaccines Prevent Disease, DEP'T OF
HEALTH & HUMAN SERVS., http://www.cdc.gov/vaccines/vac-gen/howvpd.htm (last updated Aug.
7, 2009) [hereinafter How Vaccines Prevent Disease].
49. Lisa J. Steel, Note, National Childhood Vaccine Injury Compensation Program:Is This
the Best We Can Dofor Our Children?, 63 GEO. WASH. L. REv. 144, 147 (1994).
50. How Vaccines Prevent Disease, supranote 48.
51. Calandrillo, supra note 46, at 364.
52. Id.
53. Id.
54. Id
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After Dr. Jenner's breakthrough, the use of vaccines spread quickly
in several developed countries throughout the world. In the early
1800s, many members of the United States government began to
recognize the valuable contributions of vaccines to public health. 6 In
1905, the Supreme Court held that compulsory vaccination laws by
states and municipalities were constitutional.57 By the mid-twentieth
century, elimination and control of diseases such as smallpox and polio
led to wide scale efforts towards mass immunity through the use of
To date, vaccines are credited with
compulsory vaccinations.
safeguarding humans from over twenty once-deadly diseases. 9 In
addition to saving lives, the use of vaccines has served to save billions of
dollars in resources. 6 0 Due to the many successes of vaccines, it is nearly
impossible to question their utility.61
Perhaps the most notable characteristic of vaccines is that they are
effective only when administered to the masses.62 This characteristic
caused compulsory vaccination to become standard or highly
recommended in most well developed countries. The need for "herd
immunity"6 resulted in controversy when numerous individuals began
reporting adverse reactions subsequent to a vaccination. 65 This issue is
underscored by the fact that the risk of an adverse reaction is nearly

55. Id.
56. Id. at 365.
57. See Jacobson v. Massachusetts, 197 U.S. 11, 12, 39 (1905).
58. Calandrillo, supranote 46, at 365-68.
59. Id. at 369 (stating that modem day vaccines "protect against over twenty deadly diseases,
including smallpox, measles, mumps, rubella, diphtheria, tetanus, pertussis (whooping cough),
polio, hepatitis A and B, some forms of influenza, pneumococcal disease, Haemophilus influenzae
type b, and varicella (chicken pox)").
60. Id. at 380 ("Vaccine-preventable diseases cost 16 times more in medical-related costs than
do the vaccines that prevent those diseases.").
61. See Katherine E. Strong, Note, Proving Causation Under the Vaccine Injury Act: A New
Approachfor a New Day, 75 GEO. WASH. L. REv. 426, 432 (2007) ("According to the U.S. General
Accountability Office ("GAO") vaccination in the United States has resulted in a ninety-five percent
reduction in the number of people who contract 'vaccine-preventable diseases."').
62. Id. (explaining that anyone who is not vaccinated may still catch the disease and spread it
to others). Strong references one instance in which vaccination rates dropped in the former Soviet
Union, and a diphtheria epidemic emerged that resulted in an increase of the disease from 839 cases
in 1989 to nearly 50,000 cases in 1994. Id.
63. See Calandrillo, supra note 46, at 381-83 (discussing the history of compulsory
vaccination laws in the U.S.); see also Strong, supra note 61, at 433 (noting that today most U.S.
children are vaccinated at a rate of about 57,000 children per week).
64. Strong, supra note 61, at 432 (describing the term "herd immunity" to mean that the
success of vaccines is dependent upon "virtually everyone getting vaccinated").
65. Id. at 433 (explaining that reported reactions ranged from "local reactions at the injection
sight [sic], such as redness or swelling, to more severe systemic reactions such as convulsions or
very high fevers").
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unavoidable because it is impossible to know prior to administration of
the vaccine whether a person will suffer a negative reaction to it.66
B.

Civil Lawsuits on the Rise

In the 1980s, pharmaceutical manufacturers came under fire when
countless individuals initiated lawsuits against them in civil court
claiming an adverse reaction to a vaccine. 7 These lawsuits were costly
to the vaccine manufacturers, with damage claims climbing to
approximately 3.5 billion dollars between 1980 and 1986.8 In response
to the high damage awards and fear of limitless liability in future
lawsuits, many pharmaceutical manufacturers began to seriously limit or
cease the production of vaccines. 69
With the increase in litigation, reports of adverse reactions quickly
spread to the general public, resulting in fear and lack of confidence in
vaccines. 70 Faith in vaccines also began to dwindle due to the fact that
many of the diseases that vaccines were meant to protect had been all but
eradicated.7 As a result, parents were considerably more concerned with
the potential risk of adverse reaction presented by vaccines than by the
diseases that vaccines had already eliminated.72
C. The National ChildhoodVaccine Injury Act of 1986
By 1985, the mass exodus of manufacturers from the vaccine
market left just four companies still producing the vaccines that states
had mandated for childhood immunizations. 73 As a result, vaccine

66. See H.R. REP. No. 99-908, at 6 (1986), reprinted in 1986 U.S.C.C.A.N. 6344, 6347
("There is today no 'perfect' or reaction-free childhood vaccine on the market ... it is not always
possible to predict" who will have reactions or what the reactions will be.).
67. See Derry Ridgway, No-Fault Vaccine Insurance: Lessons from the National Vaccine
Injury Compensation Program, 24 J. HEALTH POL. POL'Y & L. 59, 60 (1999) (citing relevant case
law); see generally S. A. Sturges, Comment, Vaccine-Related Injuries: Alternatives to the Tort
Compensation System, 30 ST. Louis U. L.J. 919 (1986) (describing the historical background of
vaccine manufacturer tort liability and how it gave rise to several claims including products liability,
breach of warranty, and duty to wam). Several courts even imposed strict liability upon the vaccine
manufacturers). Id.
68. Strong, supra note 61, at 434.
69. Joanna B. Apolinsky & Jeffrey A. Van Detta, Rethinking Liabilityfor Vaccine Injury, 19
CORNELL J.L. & PUB. POL'Y 537, 550 (2010).
70. Calandrillo, supra note 46, at 388.
71. Apolinsky & Van Detta, supranote 69, at 550.
72. Id.
73. H.R. REP. No. 99-908, at 7 (1986), reprinted in 1986 U.S.C.C.A.N. 6344, 6348 (noting
that, at the time, there was "only one manufacturer of the polio vaccine, one manufacturer of the
measles, mumps, rubella (MMR) vaccine, and two manufacturers of the DPT vaccine").
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production was limited and vaccine prices increased significantly.74 The
Centers for Disease Control stated that local shortages of vaccines had
been reported and indicated that certain vaccines in the vaccine
stockpiles were at below safe levels. 75 The reduction of vaccine supply
and increase in prices created concern for the state immunization
programs.76 Disruption to the vaccine supply and immunization
programs caused concern for a potential "vaccine crisis" and the
consequent increase of public susceptibility to diseases that had long
been under control or wiped out altogether.
Before the vaccine crisis could fully come to fruition, Congress
intervened by passing the National Childhood Vaccine Injury Act of
1986 ("Vaccine Act" or "Act"). The Vaccine Act legislation was
enacted in order to provide liability protection to vaccine manufacturers
and to compensate vaccine recipients who had been harmed by a
vaccine.7 9 The Vaccine Act itself contains two parts. Part One
established the National Vaccine Program that mandates continued
research of vaccines, their possible side effects, and methods for
improving vaccines.so Part Two of the Act instituted VICP." The VICP
provides a means for individuals who were potentially injured by a
82
vaccine to receive compensation.
1. Objectives and Strictures of the Vaccine Injury Compensation
Program
The principle objective of the VICP was to establish a federal nofault compensation system in which compensation would be awarded to
vaccine-injured individuals "quickly, easily, and with certainty and
Co
,,83
The Congressional intent behind the VICP was to ensure
generosity.
continued production and adequate supply of vaccines by reducing tort
litigation against physicians and manufacturers while simultaneously

74. Ridgway, supra note 67, at 61.
75. Id.
76. Strong, supra note 61, at 434.
77. Id.
78. 42 U.S.C. §300aa-1-34 (2006).
79. H.R. REP. No. 99-908, at 7 (1986), reprinted in 1986 U.S.C.C.A.N. 6344, 6348 ("[Tjwo
overriding concerns have led to the development of this legislation: (a) the inadequacy-from both
the perspective of vaccine-injured persons as well as vaccine-manufacturers-of the current
approach to compensating those who have been damaged by a vaccine; and (b) the instability and
unpredictability of the childhood vaccine market.").
80. 42 U.S.C. § 300aa-2(a)(1)-(2), (7).
81. Id § 300aa-10-34.
82. Id §300aa-10.
83. H.R. REP. NO. 99-908, at 3, reprintedin 1986 U.S.C.C.A.N. at 6344.

Published by Scholarly Commons at Hofstra Law, 2011

11

Hofstra Law Review, Vol. 39, Iss. 3 [2011], Art. 6

694

HOFSTRA LAW REVIEW

[Vol. 39:683

providing injured claimants with an opportunity for redress. " The
Vaccine Act does not eliminate a petitioner's ability to file a civil
action.85 However, civil suits are limited in two ways. First, the Act
imposes a requirement that parties first file a petition and exhaust
available remedies in Vaccine Court prior to initiation of a civil
lawsuit. 8 6 Second, the Act places modifications upon the tort theories
under which the action may be filed.
2. Filing and Deadlines
The Vaccine Act requires that individuals wishing to assert a
vaccine-related injury must file a petition in the United States Court of
Federal Claims. The petition must also be served upon the Secretary of
Health and Human Services, the named respondent in Vaccine Court
cases.89 The petition must include an affidavit and documentation that
indicates that the individual received a vaccination covered by the VICP
and that the vaccine was administered to the individual in the United
States or its trust territories. 90 The Vaccine Act set forth a thirty-six
84. See id at 13, reprinted in 1986 U.S.C.C.A.N. at 6354 (stating that "the speed of the
compensation program, the low transaction costs of the system, the no-fault nature of the required
findings, and the relative certainty and generosity of the system's awards will divert a significant
number of potential plaintiffs from litigation"); see also Div. OF VACCINE INJURY COMP.,
NATIONAL VACCINE INJURY COMPENSATION PROGRAM STRATEGIC PLAN 4 (2006), available at

http://www.hrsa.gov/vaccinecompensation/strategicjplan.htm (explaining that the mission of the
VICP is "[t]o process ... claims expeditiously and fairly utilizing current vaccine safety research to
determine injuries thought to be caused by vaccines, and raise awareness about the existence of the
VICP").
85. See 42 U.S.C. § 300aa-ll(a)(2)(A).
86. Id. ("No person may bring a civil action for damages in an amount greater than
$1,000 ... against a vaccine administrator or manufacturer in State or Federal court for damages
arising from a vaccine-related injury or death . . . unless a petition has been filed .. . for
compensation under the Program for such injury or death . . . .").
87. Id. § 300aa-22. For example, a vaccine manufacturer typically cannot be held liable under
claims of duty to warn or design defects. Victor E. Schwartz & Liberty Mahshigian, National
Childhood Vaccine Injury Act of 1986: An Ad Hoc Remedy or a Window for the Future?,48 OHIO
ST. L.J. 387, 393 (1987). In addition, vaccine manufacturers are insulated from punitive damages
provided that the vaccine complied with the requirements of the Federal Food, Drug, and Cosmetic
Act and the Public Health Service Act. Id. at 393.
88. 42 U.S.C. § 300aa-11(a)(1).
89. Id; see also id. §300aa-12(b)(1) (noting that the Secretary of Health and Human Services
is to be the named respondent).
90. Id. § 300aa-l l(c)(1)(A)-(B)(i)(l); see also National Childhood Vaccine Injury Act:
Vaccine Injury Table, HEALTH RESOURCES & SERv. ADMIN., (Nov. 10, 2008), http://www.hrsa.gov/
vaccinecompensation/table.htm (listing the vaccines currently covered under the VICP, including
tetanus toxoid-containing vaccines, pertussis antigen-containing vaccines, MMR virus-containing
vaccines in any combination, rubella virus-containing vaccines, measles virus-containing vaccines,
polio live virus-containing vaccines, polio inactivated-virus containing vaccines, hepatitis B antigencontaining vaccines, hemophilus influenzae type b, varicella vaccine, rotavirus vaccine,
pneumococcal conjugate vaccines, and any new vaccines recommended by the Centers for Disease
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month statute of limitations from the onset of injury in vaccine-related
cases.91 In instances of death, the individual's estate must file within
twenty-four months of the date of death.92
3. The Role of Special Masters
The Vaccine Act created the Vaccine Court, to adjudicate all
vaccine claims.93 The Vaccine Court is composed of one chief special
master and seven associate special masters.94 Special masters are
appointed by the U. S. Court of Federal Claims and serve four-year
terms.95 Special masters are delegated with the authority to make all
findings of fact and conclusions of law in "Vaccine Court" cases.96 Thus,
the special master appointed to a case has jurisdiction over all
proceedings, including medical records, evidence, hearings, testimony,
and all aspects of discovery. The Vaccine Act requires the special
master to reach a determination "as expeditiously as practicable, but not
later than 240 days" from the filing of the petition. If either party needs
to suspend proceedings, or if the special master is unable to render a
Control).
91. 42 U.S.C. § 300aa-16(a)(2). In May 2010, Cloer v. Secretary of Health and Human
Services, which was later vacated by the Federal Circuit, provided a more generous interpretation of
the statute of limitations, holding that "for the purposes of § 300aa-16(a)(2), to be 'vaccinerelated[,]' the 'first symptom or manifestation of onset or of the significant aggravation of such
injury' cannot occur until the medical community at large objectively realizes a link between the
vaccine and the injury." 603 F.3d 1341, 1346 (Fed. Cir. 2010), vacated, 399 Fed. App'x 577 (Fed.
Cir. Oct. 25, 2010); see also Kent Heckenlively, The Cloer Decision - When Does the Statute of
Limitations Begin to Run for Vaccine-Induced Autism?, AGE OF AUTISM (June 10, 2010, 5:45 AM),
http://www.ageofautism.com/2010/06/the-cloer-decision-when-does-the-statute-of-limitationsbegin-to-run-for-vaccineinduced-autism.html (explaining that "in plain English, Cloer is saying that
the statute of limitations cannot begin to run on a claimed vaccine injury until the medical
community at large accepts that a certain vaccine can cause that particular injury").
92. 42 U.S.C. § 300aa-16(a)(3).
93. See U.S. Court of Fed. Claims Office of Special Masters, Vaccine ProgramBackground,
U.S. CT. OF FED. CLAIMS, http://www.uscfc.uscourts.gov/sites/default/files/vaccine.background.
2010 0.pdf (last visited July 4, 2011) (noting that "[tihe Special Masters function in all respects as
the trial judges in the vaccine cases, including having final decision authority").
94. U.S. Court of Federal Claims, Vaccine Program/Oficeof Special Masters, U.S. CT. OF
FED. CLAIMS, http://www.uscfc.uscourts.gov/vaccine-programoffice-special-masters (last visited
July 4, 2011).
95. Id.
96. See H.R. REP. No. 99-908, at 16 (1986), reprinted in 1986 U.S.C.C.A.N. 6344, 6357; see
also Hodges v. Sec'y of HHS, 9 F.3d 958, 961 (Fed. Cir. 1993) ("Congress assigned to a group of
specialists, the Special Masters within the Court of Federal Claims, the unenviable job of sorting
through these painful cases and, based upon their accumulated expertise in the field, judging the
merits of individual claims.").
97. Strong, supra note 61, at 438.
98. 42 U.S.C. §300aa-12(d)(3)(A)(ii) (2006). If the special master has not reached a decision
within the 240-day period, the petitioner may elect to remain in the VICP or withdraw the petition.
Id. §300aa-12(g).

Published by Scholarly Commons at Hofstra Law, 2011

13

Hofstra Law Review, Vol. 39, Iss. 3 [2011], Art. 6

696

HOFSTRA LAW REVIEW

[Vol. 39:683

decision within 240 days, the Act provides for an extension period not to
exceed 150 days.99
The Federal Circuit sets the laws that are binding on special
masters.'o In addition, they are not bound by the Federal Rules of Civil
Procedure or the Federal Rules of Evidence.' 0 ' Instead, the Vaccine
Rules of the Office of Special Masters 0 2 were created to enable the use
of more informal procedures in vaccine cases. 0 3 The conclusions of the
special masters are generally afforded great deference by reviewing
courts.'0
4. Acceptance, Rejection, Appeals, and Compensation
After the special master has rendered his decision, the petitioner has
ninety days to file an acceptance or rejection of the judgment."s Upon
acceptance of the judgment, the petitioner is precluded from filing a civil
lawsuit against the vaccine manufacturer. 106 A petitioner may also
choose to appeal the special master's decision to the U.S. Court of
Federal Claims' 0 7 and may appeal to the Court of Appeals for the
Federal Circuit and finally, the Supreme Court of the United States.'0 8

99. Id. § 300aa-12(d)(3)(C).
100. Gary Golkiewicz, Chief Special Master, Office of Special Masters, Omnibus Autism
Proceedings Update and Implications of Causation Standard in the Program (Mar. 6, 2008)
(transcript available at http://www.hrsa.gov/vaccinecompensation/GolkewiczTranscript.htm).
101. VACCINE RULES OF THE U.S. COURT OF FED. CLAIMS tit. II, r. 8(b)(1) (2010) (providing
that "[i]n receiving evidence, the special master will not be bound by common law or statutory rules
of evidence but must consider all relevant and reliable evidence governed by principles of
fundamental fairness to both parties"); Strong, supra note 61, at 438.
102. VACCINE RULES OF THE U.S. COURT OF FED. CLAIMS tit. I-VI.
103. For example, Vaccine Rule 7(a) provides that "[tjhere is no discovery as a matter of right.
The informal and cooperative exchange of information is the ordinary and preferred practice."
VACCINE RULES OF THE U.S. COURT OF FED. CLAIMS tit. II, r. 7(a). Vaccine Rule 7(b)(1) provides
that a party who believes informal discovery is insufficient could file a formal motion to compel
discovery. Id. tit. II, r. 7(b)(1).
104. See Bradley v. Sec'y of HHS, 991 F.2d 1570, 1577 (Fed. Cir. 1993) (explaining
Congress's orders to afford a "highly deferential legal standard to the review of special masters' fact
determinations .... [W]ith regard to fact-based determinations, we defer absent a clear showing that
something went badly awry."); but see Andreu ex rel. Andreu v. Sec'y of HHS, 569 F.3d 1367,
1379 (Fed. Cir. 2009) ("While considerable deference must be accorded to the credibility
determinations of special masters, this does not mean that a special master can cloak the application
of an erroneous legal standard in the guise of a credibility determination, and thereby shield it from
appellate review.") (citation omitted).
105. 42 U.S.C. § 300aa-21(a).
106. Id. (noting that should a petitioner elect to receive compensation from the Vaccine Court,
"such person may not bring or maintain a civil action for damages against a vaccine administrator or
manufacturer for the vaccine-related injury or death for which the judgment was entered").
107. Id. § 300aa-12(e).
108. U.S. Court of Fed. Claims Office of Special Masters, supra note 93.
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Injured individuals are to be compensated out of the Vaccine Injury
Compensation Trust Fund ("Trust Fund"), which is overseen by the
Treasury Department.109 The Trust Fund revenues are generated by a
$0.75 excise tax on each dose of vaccine that is purchased."o As of
February 28, 2011 the Trust Fund was reported to contain approximately
$3.3 billion."'
The Vaccine Act provides that an injured petitioner is entitled to
recovery for medical expenses, lost wages, cost of future medical care,
and up to $250,000 for pain and suffering.1 2 Recovery for injuries that
result in death is statutorily set at $250,000." The Act does not provide
for punitive or exemplary damages."14
Attorneys may not charge fees while representing a petitioner in the
VICP."5 However, attorneys may usually recover reasonable attorneys'
fees and costs,11 6 regardless of whether the petitioner is awarded
compensation." 7 In addition, the Vaccine Court will reimburse
petitioners for the reasonable costs of scientific experts." 8 Many
petitioners alleging injuries other than an ASDs have enjoyed success in
Vaccine Court, with 2,678 petitioners being granted compensation
totaling approximately $2.07 billion as of June 2011.119

109. See 26 U.S.C. § 9510(a) (2006).
110. Dep't of Health & Human Servs., Vaccine Injury Compensation Trust Fund, HEALTH
RESOURCES & SERVS. ADMIN., http://www.hrsa.gov/vaccinecompensation/VICTrustFund.htm
(last visited July 4, 2011) [hereinaflter VICP Trust Fund] (explaining the excise tax on a vaccine that
prevents one disease is $0.75, whereas the tax on vaccines that prevent three diseases, such as the
MMR vaccine, is $2.25).
111. Dep't of Treasury, Vaccine Injury Compensation Trust Fund: 75X8175, TREASURY
DIRECT, 5 (Feb. 28, 2011), ftp://ftp.publicdebt.treas.gov/dfi/tfmb/dfivi0211 .pdf.
112. 42 U.S.C. § 300aa-15(a)(1)(A), (a)(4) (2006).
113. Id. § 300aa-15(a)(2).
114. Id. § 300aa-15(d)(1).
115. Id. § 300aa-15(e)(3).
116. As of June 2, 2011, the VICP has awarded $80,252,649.98 in attorneys' fees and costs.
VICP Statistics Report, supranote 37.
117. 42 U.S.C. §300aa-15(e)(1) (providing that attorneys may recover reasonable fees and
costs provided "that the petition was brought in good faith and there was a reasonable basis for the
claim for which the petition was brought").
118. See Kathleen Seidel, A Brief Introduction to Vaccine Court, NEURODIVERSITY WEBLOG
(Jan. 30, 2008, 14:00 PM), http://neurodiversity.com/weblog/article/142/ (quoting Chief Special
Master Gary Golkiewicz that "'[t]he expert is not given a blank check for his services and the
special masters will not sanction inflated hourly rates and limitless hours spent investigating
potential medical or scientific theories of causation').
119. VICP Statistics Report, supra note 37.
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"Table" Versus "Off Table" Claims

There are two avenues by which an individual can file a petition for
compensation. First, the petitioner may assert a claim listed under the
Vaccine Injury Table ("Table").12 0 The Table provides a list of vaccines
covered by the VICP, specific injuries known to have been the result of a
vaccine, and time constraints for the manifestation of injury
symptoms.12 1 Congress entrusted the Secretary of Health and Human
Services with the authority to amend the Table at its discretion.122 In a
Table claim, proof by a preponderance of the evidence that the petitioner
received a vaccine listed on the Table and subsequently manifested
symptoms within the given time frame creates a rebuttable presumption
that the vaccine caused the injury. 123
The second option for petitioners is to assert an "'off-table' or
"causation-in-fact" claim for injuries not listed on the Table. 12 4 This type
of claim requires proof by preponderance of the evidence that the
vaccine was the actual cause of the petitioner's injury.125 The vaccine
need not be the sole reason for the injury, but must be at least a
"'substantial factor."'l 2 6 In addition, conclusions as to causation-in-fact
are to be determined under a "legally probable, not medically or
scientifically certain" standard. 12 7 Since the Table does not currently list
120. 42 C.F.R. § 100.3(a) (2010).
121. Id. For example, the Table lists rubella virus-containing vaccines as potentially causing
chronic arthritis, with symptoms manifesting seven to forty-two days after vaccination. Id
122. 42 U.S.C. § 300aa-14(c)(1) (2006).
123. See Grant v. Sec'y of HHS, 956 F.2d 1144, 1147 (Fed. Cir. 1992) ("The Vaccine Table, in
effect, determines by law that the temporal association of certain injuries with the vaccination
suffices to show causation."); Strong, supra note 61, at 437 (explaining that the rebuttable
presumption may be defeated if the Secretary of Health and Human Services proves that the
petitioner's injury was caused by "factors unrelated" to the vaccine).
124. Gordon Shemin, Comment, Mercury Rising: The Omnibus Autism Proceeding and What
Families Should Know Before Rushing Out of Vaccine Court, 58 AM. U. L. REV. 459, 475-76
(2008).
125. 42 U.S.C. § 300aa-13(a)(1); see also Althen v. Sec'y of HHS, 418 F.3d 1274, 1278 (Fed.
Cir. 2005) (setting forth a three-prong test for proving causation-in-fact in an off-Table injury claim:
"(1) a medical theory causally connecting the vaccination and the injury; (2) a logical sequence of
cause and effect showing that the vaccination was the reason for the injury; and (3) a showing of a
proximate temporal relationship between the vaccination and injury").
126. Shyface v. Sec'y of HHS, 165 F.3d 1344, 1352-53 (Fed. Cir. 1999); see also Walther v.
Sec'y of HHS, 485 F.3d 1146, 1150 (Fed. Cir. 2007) (holding that the "Vaccine Act does not
require the petitioner to bear the burden of eliminating alternative causes where the other evidence
on causation is sufficient to establish a prima facie case").
127. See Knudsen er rel. Knudsen v. Sec'y of HHS, 35 F.3d 543, 548-49 (Fed. Cir. 1994)
(explaining that "[c]ausation in fact ... is thus based on the circumstances of the particular case,
having no hard and fast per se scientific or medical rules ... [t]he determination of causation in
fact .. .involves ascertaining whether a sequence of cause and effect is 'logical' and legally
probable, not medically or scientifically certain").
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any autism spectrum disorders or vaccines at issue in the OAP,128 ASD
claims must be asserted under the "causation-in-fact" approach.12 9
It is notable that over two-thirds of off-Table claims that come
before the Vaccine Court are dismissed.13 0 This statistic is likely due to
the fact that it is considerably more difficult to prove a causation-in-fact
injury than a Table injury for several reasons.' 3 ' For one, this approach
does not contain the presumption of causation that is available to onTable petitioners.132 In addition, the government has not already
conceded the vaccine caused the injury as they have with Table
injuries. 13 3 Thus, the proceeding becomes more adversarial as the
government defends against these claims.13 4 Moreover, statistics show
that petitioners who present testimony of an experienced medical expert
and are represented by an experienced attorney are significantly more
likely to prevail.' 35 However, many potential petitioners do not have
access to the time, funds, and resources necessary to secure seasoned
experts and attorneys.13 6
1. Federal Circuit Precedent Interpreting Causation-in-Fact
Claims
There have been several noteworthy attempts by the Federal Circuit
to interpret causation-in-fact claims. 3 7 Grant v. Secretary of Health and
128. 42 C.F.R. § 100.3(a) (2010).
129. Shemin, supranote 124, at 476.
130. James B. Currier, Too Sick, Too Soon?: The Causation Burden Under the National
Vaccine Injury Compensation Program Following De Bazan v. Secretary of Health & Human
Services, 19 FED. CIR. B.J. 229, 246-47 (2009).
131. See Hodges v. Sec'y of HHS, 9 F.3d 958, 961 (Fed. Cir. 1993) (noting the differences in
bringing Table versus off-Table claims: "[o]ne route is easy, as far as evidentiary proof
goes . . . [b]ring the case within the timetable and specifications of a Table Injury and the statute
does the heavy lifting-causation is conclusively presumed .. . [flailing that, the heavy lifting must
be done by the petitioner, and it is heavy indeed ... [g]iven the statutory burden of persuasion
placed upon the petitioner, 42 U.S.C. § 300aa-13(a)(1), and the general state of medical knowledge
about the causes of infant illness and death, it is not surprising that petitioners have a difficult time
proving cases such as this").
132. 42 U.S.C. § 300aa-13(a)(1) (2006).
133. See supra note 121 and accompanying text.
134. See Shemin, supra note 124, at 476 (citing several examples of the adversarial nature of
off-Table claims).
135. Currier, supra note 130, at 247-48 (noting that use of an experienced medical expert and
experienced attomey resulted in a 20% increase in the likelihood of compensation).
136. Id. at 248; see Brittani Scott Miller, The National Childhood Vaccine Injury
Compensation Program: The Unavailability of Experienced Attorneys Places Petitioners at an
Institutional Disadvantage, 19 FED. CIR. B.J. 253, 265 (2009) (discussing the need for more
experienced attorneys to represent VICP petitioners).
137. See Moberly ex rel. Moberly v. Sec'y of HHS, 592 F.3d 1315, 1318 (Fed. Cir. 2010);
Andreu ex rel. Andreu v. Sec'y of HHS, 569 F.3d 1367, 1374 (Fed. Cir. 2009); De Bazan v. Sec'y
of HHS, 539 F.3d 1347, 1351 (Fed. Cir. 2008); Walther v. Sec'y of HHS, 485 F.3d 1146, 1149
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Human Services, a very early Vaccine Court case, determined that the
preponderance standard is met in vaccine cases by showing "a medical
theory causally connecting the vaccination and the injury." 3 9 In
Knudsen ex rel. Knudsen v. Secretary of Health andHuman Services, 140
the Federal Circuit held that petitioners who have shown actual causation
by a preponderance of the evidence are entitled to compensation unless
the government can show by a preponderance of the evidence that "'the
injury was in fact caused by factors unrelated to the vaccine."' 4 1 Shyface
v. Secretary of Health and Human Services 42 is significant for applying
the Restatement (Second) of Torts 43 to causation-in-fact cases. 44
Specifically, Shyface determined that a petitioner is entitled to recovery
upon a showing that the vaccine was a "but for" cause of the harm and a
"'substantial factor"' in bringing about the injury.14 5 The decision in
Walther v. Secretary of Health and Human Services 4 6 noted that in
instances where there are multiple potential etiologies of the harm, the
government must prove, by a preponderance of the evidence,147 that the
vaccine did not cause the harm and must establish alternative
causation.148 Finally, the recent Vaccine Court case Andreu ex. rel.
Andreu v. Secretary of Health and Human Services 49 confirmed that the
Vaccine Rules, not the Federal Rules of Evidence, are applicable in
Vaccine Court cases.15 0

(Fed. Cir. 2007); Capizzano v. Sec'y of HHS, 440 F.3d 1317, 1328 (Fed. Cir. 2006); Pafford v.
Sec'y of HHS, 451 F.3d 1352, 1353, 1355 (Fed. Cir. 2006); Althen v. Sec'y of HHS, 418 F.3d 1274,
1279 (Fed. Cir. 2005); Shyface v. Sec'y of HHS, 165 F.3d 1344, 1348 (Fed. Cir. 1999); Terran ex
rel. Terran v. Sec'y of HHS, 195 F.3d 1302, 1308 (Fed. Cir. 1999); Knudsen ex rel. Knudsen v.
Sec'y of HHS, 35 F.3d 543, 547 (Fed. Cir. 1994).
138. 956 F.2d 1144 (Fed. Cir. 1992).
139. Id at 1148 (noting that a medical theory may be established by "proof of a logical
sequence of cause and effect showing that the vaccination was the reason for the injury"). This proof
may be derived from "evidence in the form of scientific studies or expert medical testimony." Id.
140. 35 F.3d 543 (Fed. Cir. 1994).
141. Id. at 547.
142. 165 F.3d 1344 (Fed. Cir. 1999).
143. See RESTATEMENT (SECOND) OF TORTS §§ 430-432 (1965).
144. 165 F.3d at 1351-52.
145. Id at 1352; see also RESTATEMENT (SECOND) OF TORTS § 43 1(a) (stating that "[tihe
actor's negligent conduct is a legal cause of harm to another if his conduct is a substantial factor in
bringing about the harm").
146. 485 F.3d 1146 (Fed. Cir. 2007).
147. Id.at151.
148. Id. ("[A]pplying the Restatement to the Vaccine Act context, the petitioner generally has
the burden on causation, but when there are multiple independent potential causes, the government
has the burden to prove that the covered vaccine did not cause the harm.").
149. 569 F.3d 1367 (Fed. Cir. 2009).
150. See id. at 1383 (noting the Vaccine Rule 8(b) provision that "'[i]n receiving evidence, the
special master will not be bound by the common law or statutory rules of evidence').
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2. Althen and "Close Calls"
One of the most remarkable interpretations of the Vaccine Act was
set forth in A/then v. Secretary of Health and Human Services. 5 ' A/then
postulated a three-prong test consistent with the Vaccine Act's lowered
standard of proof for causation-in-fact petitioners. 15 2 According to the
test, a petitioner may prevail by providing preponderant evidence that:
"(1) a medical theory causally connect[s] the vaccination and the injury;
(2) a logical sequence of cause and effect show[s] that the vaccination
was the reason for the injury; and (3) . . . [there is] a proximate temporal

relationship between [the] vaccination and [the] injury."' 53 The Althen
Court appreciated that in an area "bereft" of direct proof as to how
vaccines affect the human body, a requirement of anything more than
circumstantial evidence from the petitioner would impermissibly raise
the standard set forth by the Vaccine Act.154 It is also of great
significance that Althen interpreted the Congressional intent of the
Vaccine Act to be one in which "close calls" on the issue of causation
are to be "resolved in favor of injured claimants."' 5
E. The "Autism Epidemic" Explodes into the Courts
In 2002, the OSM released Autism General Order #1 ("Autism
Order")156 to address the seemingly exponential increase in the amount
of petitions asserting a causal link between vaccines and the diagnoses of
ASD.'17 The first ASD petition was filed in Vaccine Court in 1998.18 By
the time the Autism Order was issued, the number of ASD petitions had
increased to slightly over 400.'15 In 2003, the number of petitions had
expanded to 2437.160 As of June 2011, 5636 petitions have been filed
and over 5000 petitions are pending.' 6 '

151. 418 F.3d 1274 (Fed. Cir. 2005).
152. Id. at 1278.
153. Id.
154. Id. at 1280; see also Currier,supra note 130, at 238 (noting that "the Vaccine Act never
intended an 'off-table' claim to 'act as a presumption against the petitioner' . . . [b]ringing an 'offtable' claim just deprives the plaintiff of the automatic presumption of causation").
155. Capizzano v. Sec'y of HHS, 440 F.3d 1317, 1324 (Fed. Cir. 2006); Althen, 418 F.3d at
1280.
156. See Autism General Order # 1, 2002 WL 31696785, at *1 (Fed. Cl. July 3, 2002).
157. Id. (noting the "influx of [VICP] claims and the potential for many more such claims").
158. Andrus, supranote 17, at 60.
159. Bulfer, supra note 12, at 103 (noting that the 400 claims generally alleged a causal
connection between vaccines-specifically the MMR vaccine, thimerosal-containing vaccines, or a
combination of the two-and diagnosis autism spectrum disorder).
160. Andrus, supranote 17, at 60.
161. Omnibus Autism Proceeding,supranote 8; VICP Statistics Report, supra note 37.
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1. The Omnibus Autism Proceeding
The Autism Order adopted the OAP,162 a special procedure, in an
attempt to process the extreme influx of autism petitions being filed. 63
The OSM authorized a team of attorneys called the "Petitioner's Steering
Committee" ("PSC") to represent VICP petitioners.1" All five thousand
pending cases are divided between three presiding special masters. es
The OAP provides an inquiry into the "general causation issues" alleged
in the autism petitions.'66 The three original theories of causation for
establishing an association between vaccines and autism are: (1) MMR
vaccine and vaccines containing thimerosal cause autism; (2) vaccines
containing thimerosal cause autism; and (3) MMR vaccine alone causes
autism.167 On June 11, 2007, five years after the Autism Order was
issued, the Vaccine Court commenced the hearings of the OAP test
CSS168
cases.16

162. See generally Autism General Order # 1, 2002 WL 31696785, at *34 (providing the
framework for the OAP, designating Special Master Hastings to preside over the OAP, and
amending the adjudication time-frame from the original 240/420 period set forth in the Vaccine Act
to a two-year timeline in which to complete a discovery period, evidentiary hearings, and decision
on the general causation inquiry).
163. Id. at *3.
164. Id. On January 12, 2011, the OSM issued a notice that the PSC had disbanded at the end
of the OAP test case appeals. See Autism Update on Omnibus Autism Proceeding, In re Claims for
Vaccine Injuries Resulting in Autism Spectrum Disorder or a Similar Neurodevelopmental Disorder
(Fed. Cl. Jan. 12, 2011), available at http://www.uscfc.uscourts.gov/sites/default/files/
autism/Autism%20Update%201%2012%201 1.pdf. The remaining OAP cases are to be handled on a
firm-by-firm or individual basis with no participation from the OAP. Id
165. Omnibus Autism Proceeding,supra note 8; see also Cedillo v. Sec'y of HHS, 89 Fed. Cl.
158, 166 (2009) (noting the Chief Special Master designated the OAP proceedings to Special Master
Hastings, Special Master Vowell, and Special Master Campbell-Smith).
166. Autism General Order# 1, 2002 WL 31696785, at *3.
167. The Autism Proceedings:BackgroundInformation, supra note 23 (explaining the theories
of causation and noting that the third theory of causation was eventually merged with the first
theory).
168. On Theory #1 of causation, see Hazlehurst v. Sec'y of HHS, 604 F.3d 1343, 1345 (Fed.
Cir. 2010); Cedillo v. Sec'y of HHS, No. 98-916V, 2009 WL 331968, at *1, *60 (Fed. Cl. Feb. 12,
2009), af'd, Cedillo v. Sec'y of HHS, 89 Fed. Cl. 158 (2009), af'd, Cedillo v. Sec'y of HHS, 617
F.3d 1328 (Fed. Cir. 2010); Snyder v. Sec'y of HHS, 88 Fed. Cl. 706, 708 (2009). On Theory #2 of
causation, see Dwyer ex rel. Dwyer v. Sec'y of HHS, No. 03-1202V, 2010 WL 892250, at *1 (Fed.
Cl. Mar. 12, 2010); King ex rel. King v. Sec'y of HHS, No. 03-584V, 2010 WL 892296, at *1 (Fed.
Cl. Mar. 12, 2010); Mead ex rel. Mead v. Sec'y of HHS, No. 03-215V, 2010 WL 892248, at *1
(Fed. Cl. Mar. 12, 2010); see also Dep't of Health & Human Servs., Advisory Commission on
Childhood Vaccines, DEP'T OF HEALTH & HUMAN SERVS., 44 (June 10, 2010), http://www.
hrsa.gov/vaccinecompensation/ACCVTranscript-6-10-I0.pdf [hereinafter Advisory Commission on
Childhood Vaccines] (explaining that the "idea behind the test cases was to give some guidance as
to what theories had merit, what theories didn't have merit, whether there was any merit to any
theories at all").
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2. Diagnosis: Autism
Cedillo was elected by the PSC to be the first test case tried in the
OAP.169 The petitioners in Cedillo were Theresa and Michael Cedillo,
the parents of Michelle Cedillo.o Michelle's parents reported that she
was developing normally up until sixteen months of age.' 7 1 One week
after receiving the MMR vaccine Michelle developed a persistent rash
and fever.17 2 Over the following months and years, Michelle's condition
began to deteriorate further, and in 1997, Michelle was formally
diagnosed with "severe autism and profound mental retardation."l 73 In
addition to autism, Michelle suffers from gastrointestinal issues, arthritis,
glaucoma, pancreatitis, and feeding issues that require a feeding tube.174
3. Michelle's Prima Facie Case
The Cedillos filed for compensation under the Vaccine Act in
December 1998.175 Michelle's case was later consolidated into the OAP
under the theory that the MMR vaccine, along with certain thimerosalcontaining vaccines, had damaged her immune systeni.17 6 It was
Michelle Cedillo's understanding that her burden of proof would be met
when she presented a prima facie casel77 that her injuries were a result of
the MMR vaccine that was administered to her at the age of fifteen
months.' 78 To that end, Michelle's team of attorneys presented evidence
to support the medical theory that:
"(1) she was born healthy; (2) had normal development and met all
169. See Andrus, supra note 17, at 60 (noting that the PSC was permitted to present three test
cases for each of the three general theories of causation).
170. Id.
171. Cedillo, 89 Fed. Cl. at 164 (citation omitted) ("At one year, she spoke a few words,
crawled on her knees, and pulled herself to stand. She began walking at sixteen to eighteen
months.").
172. Id. (noting that the fever came and went until January 6, 1996 and was recorded at 105.7
degrees at home by her parents and 100.3 degrees by her doctor).
173. Id at 165.
174. Id.; see also Andrus, supra note 17, at 61 (commenting that "[s]ome have criticized the
PSC's selection of the Cedillo case because of the distinctiveness of Michelle's condition, which
many view as uncharacteristic of, and typically more severe, than that of other ASD Vaccine Court
petitioners").
175. Cedillo, 89 Fed. Cl. at 165. The Cedillos originally asserted that Michelle suffered from
encephalopathy, a Table Injury. Id. (internal quotation marks omitted).
176. Id. at 163, 165.
177. See Reply Brief for Petitioners-Appellants at 4-5, Cedillo v. Sec'y of HHS, 617 F.3d 1328
(Fed. Cir. 2010) (No. 2010-5004) (explaining that Michelle had presented a prima facie case by
providing "a reliable medical theory, a logical sequence of cause and effect between her MMR
vaccine and her injuries, an appropriate temporal relationship between her vaccine and the onset of
symptoms, and the absence of an alternative cause").
178. See Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009, supranote 4, at 33.
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milestones; (3) received the recommended childhood vaccinations,
many of which contained thimerosal []; (4) received an MMR vaccine;
(5) experienced fevers in excess of 105 degrees due to the MMR
vaccine; and, (6) was unable to clear
79 the measles virus [] contained in
the MMR vaccine from her body."1
The Cedillos asserted that the MMR vaccine weakened Michelle's
immune system, causing the measles virus to persist and replicate in her
body. 80 Finally, Michelle supplied evidence that the persisting measles
virus resulted in "irritable bowel disease [], inflammation in her brain,
and ultimately, autism."' 8 1
4. The Special Master's Conclusions
There is no doubt that Special Master Hastings, who presided over
the Cedillo hearings, based his findings of fact on hard evidence. 182
making his determinations, Hastings considered a three-week evidentiary
hearing that took place in June of 2007183 and reviewed approximately
7700 pages of Michelle's medical reports, hearing transcripts totaling
2917 pages, 658 medical journal articles, and post-hearing briefs totaling
462 pages.18 4 Special Master Hastings found the respondent to be more
persuasive, 8 5 concluding that the "evidence was overwhelmingly
contrary to the petitioners' contentions."' 86 However convincing the
respondent's expert witnesses were, it is noteworthy that none of the
seventeen experts for the respondent had ever personally examined
Michelle.18 7 Also, on numerous occasions in his decision, Special Master
Hastings alluded to the respondent's expert witness's credentials being
"superior" to those of the Cedillo's experts.' 8 8 After nearly ten years had
passed since Michelle had first filed for compensation, Special Master
Hastings concluded that she had failed to establish a link between her

179. Reply Brief for Petitioners-Appellants, supranote 177, at 3-4.
180. Cedillo v. Sec'y HHS, No. 98-916V, 2009 WL 331968, at *15 (Fed. Cl. Feb. 12, 2009).
181. Reply Brief for Petitioners-Appellants, supranote 177, at 4.
182. See Cedillo, 2009 WL 331968, at *14 (describing the vast evidentiary record that Special
Master Hastings considered before making his conclusions).
183. Id at*10.
184. Id. at*14.
185. Id. at *1 ("The expert witnesses presented by the respondent were far better qualified, far
more experienced, and far more persuasive than the petitioners' experts, concerning most of the key
points.").
186. Id.
187. See Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009, supra note 4, at 15-16 (noting that the respondent's experts had
based their conclusions on an examination of Michelle's eleven year old medical records).
188. See Cedillo, 2009 WL 331968, at*], *24, *58, *69, *81, *111.
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autism and the MMR vaccine and dismissed the case.18 9 Cedillo was
appealed to the Court of Federal Claims' 90 and to the Federal Circuit
where Special Master Hastings's holding was affirmed in August
2010.191
III. RISK FACTORS AND COMPLICATIONS: AN UNRESOLVED TENSION
MANIFESTS INTHE WAKE OF THE OMNIBUS AUTISM PROCEEDING
The Vaccine Act objective was essentially two-fold: (1) to protect
vaccine manufacturers from civil litigation and (2) to provide vaccineinjured individuals with a simple and straightforward method to receive
compensation.192 The Vaccine Program was advanced to alleviate the
potential risks of "'unavoidably unsafe,"" 93 but unequivocally necessary
vaccines by creating a system by which vaccine-injured individuals
could receive compensation "quickly, easily, and with certainty and
generosity." 94 By insulating pharmaceutical companies from liability,
the Program would allow manufactures to be better able to develop and
distribute vaccines.195 In fact, Congress specifically cited that the
"relative certainty and generosity of the system's awards" should divert a
significant amount of civil lawsuits.196 In addition, Congress recognized
that vaccines were extremely advantageous to public health due to their
cost-effectiveness and success at preventing catastrophic epidemics.' 9 7 It
was explicitly noted that due to their many successes, "the [fjederal
government has an interest in the development, distribution, and use of
vaccines."198
A. The Emergence of a Competing Policy Concern
At a congressional hearing in 1999, Congressman Henry Waxman,
a key sponsor of the Vaccine Act, suggested that many people today
neglect to acknowledge the value of vaccines in favor of directing their

189. Id.at*135.
190. Cedillo v. Sec'y of HHS, 89 Fed. Cl. 158, 163 (2009).
191. Cedillo v. Sec'y ofHHS, 617 F.3d 1328, 1334 (Fed. Cir. 2010).
192. See H.R. REP. No. 99-908, at 3-4 (1986), reprintedin 1986 U.S.C.C.A.N. 6344, 6344.
193. See id. at 26, reprinted in 1986 U.S.C.C.A.N. at 6367 (explaining that the term
'unavoidably unsafe' products, i.e. those products which in the present state of human skill and
knowledge cannot be made safe appl[ies] to the vaccines covered in the bill and that such products
not be the subject of liability in the tort system").
194. Id at 3, reprinted in 1986 U.S.C.C.A.N. at 6344.
195. Id at 7, reprinted in 1986 U.S.C.C.A.N. at 6348.
196. Id at 13, reprinted in 1986 U.S.C.C.A.N. at 6354.
197. Id at 4-5, reprinted in 1986 U.S.C.C.A.N. at 6345-46.
198. Id. at 5, reprinted in 1986 U.S.C.C.A.N. at 6346.
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focus to the potential risks.' 99 Congressman Waxman expressed his
concern that "if children are frightened and parents discouraged about
vaccines, we will quickly become vulnerable again to infectious
diseases."200 In 2008, Chief Special Master Gary Golkiewicz made an
address to the Advisory Commission on Childhood Vaccines. 20' The
address expounded upon the policy concerns that Congressman Waxman
had articulated in his statement nearly ten years earlier.202 Golkiewicz
discussed a policy concern he called "protecting the vaccine's
integrity .. . that is that vaccine[s] do[] not cause every injury that
follows immunization."2 03 The Chief Special Master defended his views
on the theory that generous remuneration to vaccine-injured petitioners
may weaken public confidence in vaccines. 2 04 Golkiewicz's unease was
also likely in response to survey results indicating the public felt an
increasing body of concern as to the safety of vaccines.205 It is clear from
this address that special masters feel the pressure between compensating
vaccine-injured petitioners and sustaining public confidence in
vaccines.206
Based on a reading of the legislative history, it seems Congress
recognized that upholding the use of vaccines was a relevant policy
concern. 2 0 7 In fact, Congress specifically noted that the use of vaccines
199. See Vaccines-Findingthe Balance Between Public Safety andPersonalChoice: Hearing
Before the H. Comm. on Gov't Reform, 106th Cong. 14 (1999) (statement of Congressman Henry H.
Waxman) (asserting that "today we are becoming complacent about our success against infectious
diseases .. . [u]nlike our parents and grandparents, we aren't terrorized every year by paralytic polio
and whooping cough epidemics ... [t]his makes it easier to forget the value of vaccines and focus
on their potential risks"); see also Calandrillo,supranote 46, at 438-39 ("Today, one is more likely
to hear about vaccine safety risks than she is about vaccine benefits . .. [t]he media and internet
highly publicize stories regarding links between immunizations and autism, leading well-meaning
parents to question whether the cure is worse than the disease.").
200. Vaccines-Finding the Balance Between Public Safety and Personal Choice: Hearing
Before the H. Comm. on Gov't Reform, supra note 199.
201. Golkiewicz, supra note 100.
202. Id.
203. Id
204. See id; see also Brief of Amici Curiae Elizabeth Birt Ctr. for Autism Law and Advocacy,
et al. in Support of Appellants and in Favor of Reversal at 15, Cedillo v. Sec'y of HHS, 617 F.3d
1328 (Fed. Cir. 2010) (No. 98-916V), available at http://www.rescuepost.com/files/filed-cedilloamicus-brief-2.pdf (explaining the "divided loyalties" of special masters in compensating vaccineinjured petitioners due to the competing policy concern of protecting vaccine integrity).
205. See Allen, supra note 39 (noting that a 2008 survey conducted by APCO Insight indicated
that at least 18% of parents had changed their vaccine practices due to safety concerns). This was a
6% increase from 2006 when the same survey found that only 12% of parents had changed their
vaccine practices as a result of safety concerns. Id.
206. Golkiewicz, supra note 100.
207. See See H.R. REP. No. 99-908, at 5 (1986), reprinted in 1986 U.S.C.C.A.N. 6344, 6346
(noting five principal findings that formed the basis ofthe Vaccine Act).
It was determined that legislation was needed in the area of vaccines because: "(1) [t]he
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was necessary to prevent diseases and that access to vaccines was a
responsibility of the federal government.2 08 However, the primary
concerns of Congress, as articulated in the House Report, were to
stabilize the vaccine market and compensate those injured by
vaccines.209 Nonetheless, Congress should have recognized the
likelihood that a policy such as upholding the use of vaccines may clash
with the Act's primary objectives and prepared a way to minimize or
210
alleviate this inevitable tension. Instead, the issue was left unresolved
and has now trickled down to the special masters,2 11 whose role is
limited to "apply[ing] the law." 2 12 The fact that there are competing
policies may be unavoidable, but special masters should not be left to
strike a balance between them.213
B. The Fine Line Between the Policies
The Cedillo case alone has experienced tremendous amounts of
exposure214 and much speculation that an award of compensation in that
availability and use of vaccines to prevent childhood diseases is among the Nation's top public
health priorities[;] (2) [t]he Federal government has the responsibility to ensure that all
children in need of immunization have access to them and to ensure that all children who are
injured by vaccines have access to sufficient compensation for their injuries[;] (3) [p]rivate or
non-governmental activities have proven inadequate in achieving either of these goals [(I) and
(2);] (4) [c]urrent economic conditions have resulted in an unstable and unpredictable
childhood vaccine market, making the threat of vaccine shortages a real possibility[; and] (5)
[b]ecause of their cost-effectiveness, the Federal government has an interest in the
development, distribution, and use of vaccines, including those designed to prevent nonchildhood diseases.
Id., reprintedin 1986 U.S.C.C.A.N. at 6346.
208. See id., reprinted in 1986 U.S.C.C.A.N. at 6346.
209. See id. at 7, reprintedin 1986 U.S.C.C.A.N. at 6348.
210. See infra Part V.
211. See Golkiewicz, supra note 100 (articulating that "[t]here's a tension between these two
objectives, a tension that affects dramatically the litigation of the cases, the parties' arguments and
ultimately who wins").
212. See Althen v. Sec'y of HHS, 418 F.3d 1274, 1280 (Fed. Cir. 2005) (explaining that "[tlhe
special master's role is to apply the law . .. [q]uestions of law regarding the interpretation or
implementation of the Vaccine Act are matters for the courts").
213. See VACCINE RULES OF THE U.S. COURT OF FED. CLAIMS tit. II, r. 3(b) (2010) (listing the
special master's duties as: "(1) conducting all proceedings, including taking such evidence as may
be appropriate, making the requisite findings of fact and conclusions of law, preparing a decision,
and determining the amount of compensation, if any, to be awarded; and (2) endeavoring to make
the proceedings expeditious, flexible, and less adversarial, while at the same time affording each
party a full and fair opportunity to present its case and creating a record sufficient to allow review of
the special master's decision").
214. Cedillo and the autism cases have received a significant amount of attention from several
media outlets. For example, both Oprah Winfrey and Larry King have featured autism on their
television programs, and several television shows have featured portrayals of autistic characters,
including NBC's Parenthood and ABC's Grey's Anatomy. Grey's Anatomy: All by Myself (ABC
television broadcast Dec. 4, 2008); Larry King Live: Autism Breakthroughs (CNN television
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case would have a disastrous impact on the future of the VICP. 215 The
publicity that has been afforded to the OAP and Cedillo has undoubtedly
left the special masters well aware that a positive outcome for petitioners
may result in the same fear of vaccines that drove down immunization
rates in the 1980s. 2 16 On the other hand, the special masters also know
that a definitive finding of no causal link between vaccines and autism in
a highly publicized case like Cedillo would serve to bolster public
confidence and provide reassurance2 17 that vaccines are safe.218
In addition to the fear of dwindling public confidence in vaccines,
another overriding concern has been the very real likelihood that the
autism cases, if compensated, would quickly bankrupt the Trust Fund.219
However, if petitioners are unable to receive compensation via the
Vaccine Court, there is a substantial possibility that civil lawsuits against
vaccine manufacturers will be on the rise once again.220 Consequently,
broadcast Feb. 28, 2008); Oprah Winfrey Show: Mothers Battle Autism (ABC television broadcast
Sept. 18, 2007); Parenthood Pilot(NBC television broadcast Mar. 2, 2010).
215. See Regina Moreland, Comment, National Vaccine Injury Compensation Program: The
PotentialImpact of Cedillo for Vaccine-Related Autism Cases, 29 J. LEGAL MED. 363, 377-79
(2008) (explaining that if Cedilla were to establish a general causation link between vaccines and
autism, the VICP would be detrimentally impacted because the Trust Fund is insufficient to
compensate the autism cases and the Court of Federal Claims will be unable to handle the extreme
influx of cases).
216. See Meredith Daniels, Note, Special Masters in the National Vaccine Injury
Compensation Program:Placinga Heightened Burden on Vaccine ProgramPetitionersby Straying
from Precedent and CongressionalIntent, 6 J. HEALTH & BIOMED. L. 79, 105-06 (2010); see also
Kevin Conway, CODA: The Injustice Continues, 33 THE AUTISM FILE 49, 50 (2009) ("Due to the
extraordinary publicity this issue had received, officials feared parents would refuse to immunize
their children, that immunization rates would fall, and that preventable diseases would return.");
Gardiner Harris, Measles Cases Grow in Number, and Officials Blame Parents' FearofAutism,
N.Y. TIMES, Aug. 22, 2008, at A16 (discussing how the growing body of concern over the safety of
vaccines has caused many parents to refuse to vaccinate their children).
217. See Statement from the Department of Health and Human Services Regarding the
Decisions of the U.S. Court of Federal Claims in the Omnibus Autism Proceeding,U.S. DEP'T OF
HEALTH & HUMAN SERVS., (Feb. 12, 2009), http://www.hhs.gov/news/press/2009pres/02/
20090212a.html ("Hopefully, the determination by the Special Masters will help reassure parents
that vaccines do not cause autism.").
218. Compare Allen, supra note 39 (explaining the hope that the ruling against Cedillo will
reverse the trend of parents refusing to vaccinate their children), with Brief of Amici Curiae
Elizabeth Birt Ctr. for Autism Law and Advocacy, et al. in Support of Appellants and in Favor of
Reversal, supra note 204, at 4, 16 (asserting that "Michelle's case exemplifies the conflict of interest
in the Program between compensating victims and protecting the vaccine program. .. . [t]o rule in
Michelle's favor is to reaffirm that vaccines are not harmless, and that they do sometimes cause
adverse reactions").
219. Moreland, supra note 215, at 378-79 (noting that there are approximately 560,000 people
with autism in the United States). Moreover, if each of these people were to file for compensation
under the OAP and receive the average amount of compensation that has been awarded to other
petitioners in the VICP, the Trust Fund (which is currently valued at approximately $3.3 billion)
would have to pay out $4,328,800,000,000,000. Id.
220. See Daniels, supra note 216, at 105-06; see also Shemin, supra note 124, at 464 (noting
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the ability of vaccine manufacturers to produce adequate supplies of
vaccines and continue vaccine research may again be hindered, placing
the vaccine supply and public health in jeopardy yet again.22 1
IV.

SIDE EFFECTS: CEDILLO ILLUSTRATES THE TENSION

Cedillo provides an excellent demonstration of the tension that has
been left unresolved.2 22 Instead of striking a balance between the
competing policies, Congress has thrust them upon the special masters,
without any guidance, to be resolved under the guise of fact-finding. 2 23
Due to the lack of guidance, a special master presiding over a case may
be swayed towards making a finding based on whichever policy concern
he chooses to emphasize. Althen sought to limit this issue by reasoning
that "close calls regarding causation are resolved in favor of injured
claimants."224 Althen's direction regarding "close calls" was based on the
understanding that the system created by Congress was one in which
circumstantial evidence was adequate to meet the petitioner's burden. 22 5
Special Master Hastings undeniably considered a great deal of hard
evidence 22 6 and ultimately opined that Cedillo was "not a close case."227
However, reasonable minds could differ on this issue, as an examination
of the record reveals that Cedillo is replete with instances of what might
be "close calls" under Althen.228 Michelle Cedillo concedes there is
currently no direct evidence to substantiate the claim that vaccines can
cause autism. 229 However, Althen and its progeny 230 instruct that a

that if the Cedillos are not awarded compensation, it is likely that many petitioners will opt out of
the Vaccine Court and bring their claim in civil court ... [i]n civil court, petitioners may be able to
obtain necessary discovery documents that would probably have been denied in vaccine court, have
their trial decided by a jury, and be entitled to greater damage awards); Reply Brief for PetitionersAppellants, supranote 177, at 3.
221. Daniels, supra note 216, at 106.
222. See Brief of Amici Curiae Elizabeth Birt Ctr. for Autism Law and Advocacy, et al. in
Support of Appellants and in Favor of Reversal, supra note 204, at 4.
223. See VACCINE RULES OF THE U.S. COURT OF FED. CLAIMS tit. II, r. 3(b)-(d) (2010) (listing
the duties of the special master in Vaccine Court cases, none of which include making policy
determinations).
224. Id. at 1280.
225. See id.
226. See discussion supraPart II.E.4.
227. Cedillo v. Sec'y of HHS, No. 98-916V, 2009 WL 331968, at *134 (Fed. Cl. Feb. 12,
2009) (noting that "this is a case in which the evidence is so one-sided that any nuances in the
interpretation of the causation case law would make no difference to the outcome of the case").
228. See discussion infra Part IV.A-D.
229. Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009, supra note 4, at 32-33.
230. See Andreu ex rel. Andreu v. Sec'y of HHS, 569 F.3d 1367, 1370 (Fed. Cir. 2009);
Capizzano v. Sec'y of HHS, 440 F.3d 1317, 1319 (Fed. Cir. 2006).
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petitioner need not offer direct evidence.231 Instead, a petitioner need
only offer proof of causation by a preponderance of circumstantial
evidence.232 The fact that the autism cases are characterized by so many
gaps in evidence 23 3 means that there are many various "close calls" that
could sway the special master in either direction. The purpose of this
Note is not to second-guess Special Master Hastings's conclusions of
fact, but rather to illustrate examples of "close calls" within Cedillo
where fundamental policy clashes could have influenced the findings.
A.

Unigenetics and the Uhlmann Article

Many of the respondent's experts' opinions and Special Master
Hastings's conclusions were based on the alleged unreliability of the
data from the Unigenetics Ltd.234 laboratory ("Unigenetics") in
Ireland. 2 3 5 However, much of Michelle's case was dependent upon the
reliability of a test conducted at the Unigenetics lab.236 Unigenetics's
credibility has been questioned due to the controversial article authored
by V. Uhlmann and his colleagues in 2002 ("Uhlmann Article") 2 37
providing support for the proposition that the MMR vaccine causes
autism. 2 38 The Unigenetics test of Michelle's intestinal tissue indicated a
continuing presence of measles virus RNA in Michelle's gut. 23 9 The
presence of measles virus RNA in Michelle's tissue is essential to the
231. See Althen v. Sec'y of HHS, 418 F.3d 1274, 1279-80 (Fed. Cir. 2005).
232. Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of Feb. 12, 2009, supra note 4, at 33.
233. See generally Bartholomew C. Wacek, Comment, Taking Sides in the Vaccine/Autism
Legal Battle, 8 DEPAUL J. HEALTH CARE L. 305 (2004) (summarizing the theories and scientific
studies for and against a causal relationship between vaccines and autism). Evidence is further
confused by the recent government's concession that the MMR vaccine aggravated an existing
condition in a young girl and resulted in autism. See Donovan, supranote 30, at 248-49.
234. See Cedillo v. Sec'y of HHS, No. 98-916V, 2009 WL 331968, at *26 (Fed. Cl. Feb. 12,
2009) (explaining that Unigenetics is a laboratory run by Dr. John O'Leary and his colleagues) In
2002, Unigenetics tested a sample of Michelle Cedillo's gut tissue for the detection of measles virus.
The results of the test indicated that measles virus RNA had been detected in Michelle's intestinal
tissue. Cedillo, 2009 WL 331968, at *26.
235. Id
236. See Brief of Amici Curiae Elizabeth Birt Ctr. for Autism Law and Advocacy, et al. in
Support of Appellants and in Favor of Reversal, supranote 204, at 17-22.
237. See V. Uhlmann et al., Potential Viral Pathogenic Mechanism for New Variant
Inflammatory Bowel Diseases, 55 J. CLINICAL PATHOLOGY 84, 87-88 (2002). The Uhlmann Article
was co-authored by eleven people, including Andrew Wakefield. The Uhlmann Article published
the findings of the O'Leary laboratory tests indicating a presence of measles virus RNA in the gut
tissue of most of the developmentally disabled children who were tested. Cedillo, 2009 WL 331968,
at *31 (noting that the same type of testing, called polymerase chain reaction was conducted on
Michelle Cedillo's gut tissue).
238. See Cedilla, 2009 WL 331968, at *32; see also Wakefield, supra note 25, at 637.
239. Cedillo, 2009 WL 331968, at *30.
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Cedillo's medical theory that intestinal inflammation played an
etiological role in the development of her autism. 2 40
In response to the Uhlmann Article, the respondent provided
testimony from Dr. Stephen Bustin, a Ph.D. molecular biologist, who
personally studied the Unigenetics lab, the lab's equipment, and all of
the data compiled by the Uhlmann researchers.241 Dr. Bustin testified
that there were serious defects with regard to Unigenetics's measles
virus detection and that the data was not reliable.242 Dr. Bustin also
alleged that contamination was "rampant" in the Unigenetics lab. 243
However, Dr Bustin could only identify one episode of contamination in
the Unigenetics laboratory notebooks. 24
No other evidence has been submitted to support Dr. Bustin's
conclusion that Unigenetics has contamination issues.24 5 In fact, multiple
experts acknowledged that some contamination occurs in every lab, and
every lab has set protocol to eliminate contamination.246 In addition, Dr.
Bustin's testimony was refuted by that of Dr. Ronald Kennedy, a Ph.D.
in microbiology, who testified that Unigenetics lab had taken appropriate
241
measures to minimize contamination. It is clear that the petitioner and
respondent presented conflicting reports concerning the reliability of the
Unigenetics data.248 Ultimately, each of the arguments contained enough
evidence that the issue of Unigenetics's reliability could qualify as a
"close call" under Althen.249
B.

Was Unigenetics's Test Unable to be Replicated?

In addition to Dr. Bustin's testimony, the respondent provided other
experts to discount the Unigenetics lab and offered evidence that other
laboratories were unable to replicate the results of Unigenetics findings
with respect to measles virus RNA detection. 25 0 The respondent's
240. Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009, supranote 4, at 32, 34-35.
241. Cedillo, 2009 WL 331968, at *35.
242. Id. at *36.
243. Id.
244. Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009, supra note 4, at 46; see also Cedillo, 2009 WL 331968, at *36
(noting Dr. Bustin's theory that the laboratory notebooks had been altered to potentially conceal
instances of contamination).
245. Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009, supranote 4, at 46 n.62 and accompanying text.
246. Id. at 46.
247. Cedillo, 2009 WL 331968, at *34.
248. See supra Part W.A.
249. See Althen v. Sec'y of HHS, 418 F.3d 1274, 1280 (Fed. Cir. 2005).
250. Cedillo, 2009 WL 331968, at *40.
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experts asserted that two independent research teams, as well the Cotter
laboratory and the Oldstone laboratory, had attempted to replicate
Unigenetics's findings to no avail. 2 5 1 The Cedillos disputed this
information based on the fact that both the Cotter and Oldstone
laboratories were able to replicate the test results with respect to high
copy numbers.252 Copy number variation is determined by conducting a
polymerase chain reaction ("PCR") 253 test on a sample of biologic
tissue.25 4 The copy number is "derived from a ratio between the number
of actual copies found of the target, such as the F-gene of the measles
virus, and the number of copies found of a 'housekeeping gene' (which
is found in all cells of the body)."25 5 The Cedillos assert that the high
copy number of measles virus on her sample tissue is evidence that the
virus remains active in her body.2 56
In his testimony, Dr. Bustin reported that he only questioned
Unigenetics with respect to low copy numbers, and admitted that
Michelle had high copy numbers. 257 Dr. Bustin also acknowledged that
"[h]igh copy numbers are considered accurate because the detection of
RNA occurs at a lower cycle number ... earlier in the experiment, and
makes them inherently reliable."2 58 Nevertheless, Special Master
Hastings did not find the high copy number argument to be
persuasive.259 Special Master Hastings agreed with testimony from Drs.
Brian Ward and Bertus Rima, both of whom were experts for the
respondent, suggesting that evidence of a high copy number does not
necessarily confirm that a test is reliable.260 In addition, Special Master
Hastings gave no credit to the Cotter and Oldstone laboratory
replications because the findings were never published.2 6 1 In sum,
Special Master Hastings was offered inconsistent accounts regarding the

251. Seeid at*40-41.
252. Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009, supranote 4, at 46.
253. See Gerald Schochetman, Chin-Yih Ou & Wanda K. Jones, Polymerase Chain Reaction,
158 J. INFECTIOUS DISEASES, 1154, 1154 (1988) (explaining that the PCR was developed in the
1980s for "in vitro amplification of the DNA or RNA of an organism or gene defect .... [tihe PCR
takes advantage of an enzyme that uses a defined segment in a strand of DNA as a template for
assembling a complementary strand").
254. Cedillo, 2009 WL 331968, at *50.
255. Id
256. Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009, supra note 4, at 48.
257. See id. at 43.
258. Id.
259. Cedillo, 2009 WL 331968, at *51.
260. Id. at *50-51.
261. Id. at *41.
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reliability of high copy numbers.2 62 The evidence to support both
arguments was such that it gave rise to a "close call" in which Special
Master Hastings could have tipped the scale in either direction.263
C. Presence ofMeasles Virus RNA and the Possibilityof Virus
Replication
Michelle's expert, pediatric neurologist Dr. Marcel Kinsbourne,
testified that the persisting measles virus in Michelle's body eventually
entered her brain. 264 Dr. Kinsbourne testified that in response to the
persisting measles virus, Michelle's immune system produced
inflammation, which "disorganized certain critical circuits in her brain"
and resulted in autism.265 Special Master Hastings was unconvinced by
Dr. Kinsbourne's theory, and instead afforded great deference to the
respondent's expert Dr. Diane Griffin, a medical doctor who specializes
in biology, immunology, and virology.266 Dr. Griffin testified that the
presence of measles virus RNA in Michelle's intestinal tissue alone is
not indicative of disease.267 Instead, Dr. Griffin stated that the presence
of protein is also necessary in order for the virus to persist and
replicate.2 68 However, Dr. Griffin's statement was contradictory to an
article she co-authored, stating in part "the presence of measles virus
RNA represents continued measles virus replication.",2 69 In addition, Dr.
Griffin admitted that she had not reviewed the Uhlmann Article, and was
therefore oblivious to the fact that the Unigenetics lab had in fact found
protein in Michelle's intestinal tissue.2 70 In this case, the "close call" was
precisely whether Special Master Hastings should have afforded more
271
weight to Dr. Kinsbourne's theory or to Dr. Griffin's testimony.
D. Does Michelle Have Inflammatory Bowel Disease?
The Cedillos also presented evidence that the persisting measles
virus from her MMR vaccine caused Michelle to suffer from
262. See supra Part IV.B.
263. See discussion supra Part IV.
264. Cedillo, 2009 WL 331968, at *65 (explaining that Dr. Kinsbourne's theory relied heavily
on the Unigenetics lab results indicating a persisting presence of measles virus RNA in Michelle's
body).
265. Id.
266. See id. at *68, *83.
267. Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009, supra note 4, at 39.
268. Id.
269. Id.
270. Id. at 50.
271. See supra Part IV.C.
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inflammatory bowel disease ("IBD").272 The Cedillos have asserted that
the fever Michelle experienced after receiving the MMR vaccine could
have damaged her immune system, thus impeding her body's ability to
clear the measles virus and allowing it to persist and replicate.273
Michelle's argument was dependent on the theory that "[t]here is a
strong relationship between the immune system, gastrointestinal
disorders, and autism."274 Dr. Byers, an expert witness for the Cedillos,
expressed the view that IBD may be evidence of an abnormal immune
system. 275 Thus, proof that Michelle suffers from IBD would bolster her
claim that her chronic inflammatory conditions were evidence of her
body's inability to clear the MMR vaccine.27 6
The respondent's expert Dr. Hanauer, an adult gastroenterologist,
denied that viruses might cause IBD.277 This statement directly
contradicted a 2006 article authored by Dr. Hanauer in which he
expressed the view that IBD can be triggered by "'a chronic
inflammatory response precipitated by [an] infection with a particular
pathogen or virus.,,278 Dr. Hanauer denied that Michelle has IBD at all

based on the lack of inflammation on Michelle's pathology slides.2 79
However, he did admit that Michelle suffers from other conditions,
including arthritis and eye disorders, which are commonly associated
with IBD. 280 In addition, both Dr. Hanauer and Special Master Hastings
neglected to recognize that Michelle has been prescribed a drug
treatment called Remicade to treat her IBD. 2 8 1 Remicade is likely
responsible for the lack of inflammation on her pathology report.282
Thus, Special Master Hastings was presented with evidence amounting
to a "close call" as to whether a virus may trigger IBD and whether
Michelle has IBD at all. 283

272. See Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009, supra note 4, at 34, 53 (asserting that Michelle's current treating
gastroenterologist Dr. Ziring has no doubt that Michelle has IBD).
273. See Cedillo v. Sec'y of HHS, No. 98-916V, 2009 WL 331968, at *16 (Fed. Cl. Feb. 12,
2009).
274. Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009, supra note 4, at 64.
275. See Cedillo, 2009 WL 331968, at *26.
276. Id.
277. Petitioners' Memorandum in Support of Motion for Review of the Special Master's
Decision of February 12, 2009, supra note 4, at 35.
278. See id. at 35.
279. Id. at 54.
280. Id at 36.
281. Id at 53, 55.
282. Id. at 55.
283. See discussion supra Part IV.D.
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TREATMENT OPTIONS FOR ALLEVIATING THE SPECIAL MASTERS'
TENSION

It is undeniable that the future of the OAP means a great deal to a
countless number of people whose lives have been affected by autism.
The remaining five thousand petitioners in the OAP still await their day
in court with a glimmer of hope that they will receive compensation to
help alleviate the many financial burdens of the disorder.2 8 4 As a test
case, it was determined that Cedillo failed to establish the causal
relationship between vaccines and autism upon which so many other
claims in the OAP are dependent. 2 85 Nevertheless, Cedillo is significant
for revealing that the inadequately resolved tension between
incompatible policies has fallen unreasonably on the shoulders of the
special masters presiding over the OAP.286
The tensions between the two policies are difficult to reconcile, as
they are inherently at odds with one another. At surface level, the driving
principle behind the Vaccine Act was to ensure continued production
and supply of vaccines and simultaneously provide compensation for
individuals who have been injured by a vaccine. 287 Going deeper, the
legislative history of the Act acknowledges that there is an interest in
288
promoting the use of vaccines to prevent childhood diseases.
However, the use of vaccines is necessarily dependent upon the public's
recognition that the benefits of vaccines outweigh the risks. Thus, it is
not difficult to sense the special masters' dilemma-even a slight
concession that suggests a causal relationship between vaccines and
autism may emasculate the publics' confidence in the safety vaccines.

284. See Bortfeld, supra note 15 (noting that the lifetime cost of treatment for autism ranges
from three to seven million dollars); see also Catherine Lord & Somer L. Bishop, Autism Spectrum
Disorders:Diagnosis,Prevalence, and Servicesfor Children and Families, 24 Soc. POL'Y REP. No.
2, 2010 at 1, 11 (explaining that most insurance packages provide little or no coverage for autism
related expenses and in fact, employers are permitted to set up "'autism riders.' when negotiating
employee health insurance plans); Insurance Coverage for Autism, NAT'L CONF. OF STATE
LEGISLATURES (Nov. 2010), http://www.ncsl.org/?tabid=18246 (describing that legislation has been
enacted in several states since 2007 mandating insurance companies to provide some coverage for
autism, but, the coverage provided is still insufficient to cover the majority of autism related
expenses); Economics of Autism, THE SMART FOUNDATION, http://www.thesmartfoundation.org/
Challenges/Economics.htm (last visited July 4, 2011) (estimating that 87% of families with autism
subsist at poverty level).
285. See supra Part II.E.2, II.E.4.
286. See supra Part IV.
287. See H.R. REP. No. 99-908, at 7 (1986), reprinted in 1986 U.S.C.C.A.N. 6344, 6348.
288. Id at 5, reprintedin 1986 U.S.C.C.A.N. at 6346 (noting that legislation was needed in the
area of vaccines because "[t]he availability and use of vaccines to prevent childhood diseases is
among the Nation's top public health priorities ... [b]ecause of their cost-effectiveness, the Federal
government has an interest in the . . . use of vaccines") (emphasis added).
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A. A Workable Solution
Going forward, it is evident that special masters need more
guidance from some authority as to how to strike the balance between
the two policies in causation-in-fact cases. Precedent has clearly
established that the task of creating more rules is a responsibility for the
Federal Circuit, not the special masters.2 89 Striking the balance between
the policies is not an issue that requires new legislation or a revision of
the Vaccine Act. The clearest answer to the situation at hand is a process
solution in which the Federal Circuit steps in to provide more rules for
the special masters to apply when making their findings of fact.
1. What is a "Close Call," Anyway?
Causation-in-fact claims have represented an undoubtedly murky
territory in the history of Vaccine Court.29 0 As noted previously, the
Federal Circuit has made several attempts to carve out rules to interpret
the statutory language provided in the Vaccine Act. 2 9 1 For example, in
Althen, the Federal Circuit altered the legal landscape by providing
special masters with useful guidance on fact-finding by setting forth the
three-prong test for a showing of causation-in-fact.292 In the same vein,
the Federal Circuit attempted to provide more guidance by determining
that "the system created by Congress, [is one] in which close calls
,,293
regarding causation are resolved in favor of injured claimants.
Interestingly, a careful review of Althen suggests that the Federal Circuit
has in fact made some attempt to strike a balance between the competing
policies. If "close calls" are to be weighed in favor of the petitioner, it
seems that the Federal Circuit has determined that compensation of the
-294
injury is more important than protecting the integrity of vaccines.
289. Althen v. Sec'y of HHS, 418 F.3d 1274, 1281 (Fed. Cir. 2005) ("The special master's role
is to assist the courts by judging the merits of individual claims on a case-by-case basis, not to craft
a new legal standard to be used in causation-in-fact cases."); see also Golkiewicz, supra note 100
(remarking that "the Federal Circuit sets the law that's binding on the special masters and the
parties").
290. See Currier,supranote 130, at 237-40 (summarizing a brief history of case law regarding
causation-in-fact claims).
291. See discussion supra Part II.D.I.
292. See discussion supra Part II.D.2.
293. Althen, 418 F.3d at 1280. This statement was based on Althen's understanding of the early
Vaccine Court case Knudsen ex rel. Knudsen v. Secretary ofHealth and Human Services which held
that "to require identification and proof of specific biological mechanisms would be inconsistent
with the purpose and nature of the vaccine compensation program." Knudsen ex rel. Knudsen v.
Sec'y of HHS, 35 F.3d 543, 549 (Fed. Cir. 1994).
294. Currier, supra note 130, at 240 (discussing how compensation is tipped in favor of
claimants such that "scholars have noted that there has been an increasing trend in vaccine courts in
favor of granting compensation ... [t]his trend is an unavoidable and laudable result of the history
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The "close call" recommendation has become something of a
catchphrase as several recent cases have cited to it.295 However, analysis
of Cedillo demonstrates that the common idiom "close call" is actually
quite subjective and leaves too much room for interpretation.296
Ultimately, the phrase loses most of its utility in the sense that there have
been no real attempts to clarify it. Instead of expounding upon its
meaning or creating a working definition of it, the Federal Circuit cases
that have cited Althen regarding "close calls" have simply quoted the
original text.297 Without clarification of what actually constitutes a
"close call," special masters have no way of consistently applying it to
their conclusions in causation-in-fact cases.298
This paradox played out in Cedillo, a case that arguably contained
several "close calls."299 If "close calls" were truly to weigh in favor of
the petitioner, Michelle Cedillo might have won her case. However,
Special Master Hastings was of the opinion that there were no real "close
calls." 3 00 The idea of a "close call" is so ambiguous that some special
masters may feel that they can either ignore it or assign it very little
weight when making their conclusions.3 01 In his 2008 address, Chief
Special Master Golkiewicz remarked, "there's clearly plenty of
interpretative room left in the Federal Circuit's opinions. And that means
parties looking at the same evidence are reaching different
conclusions." 0 2 Thus, the Federal Circuit must be prompted to establish
a definition or test to clearly delineate what constitutes a "close call" and
how a special master might recognize one. In addition, the clarification
and text of the Vaccine Act ... Congress's response to the vaccine 'crisis' of the 1980s
demonstrates that the federal government would rather pay uncertain claims than revert back to a
tort system that simultaneously burdens vaccine manufactures, civil courts, and the general public").
In fact, Chief Special Master Golkiewicz alluded to this when he stated, "I think it's fair to say that
the recent Fed Circuit opinions lean more heavily towards promoting of vaccine[s] by setting a
standard whereby more cases are compensated. Thus, the pool of potential cases for seeking redress
against the manufacturer or administrator is reduced." Golkiewicz, supranote 100.
295. See Andreu ex rel. Andreu v. Sec'y of HHS, 569 F.3d 1367, 1378 (Fed. Cir. 2009);
Walther v. Sec'y of HHS, 485 F.3d 1146, 1150 (Fed. Cir. 2007); Capizzano v. Sec'y of HHS, 440
F.3d 1317, 1324 (Fed. Cir. 2006).
296. See supra Part IV.A-D.
297. See Andreu, 569 F.3d. at 1378; Walther, 485 F.3d at 1150; see also Capizzano, 440 F.3d
at 1324.
298. See Golkiewicz, supra note 100 (noting that following the Althen decision, there still
remains a great deal of uncertainty as to how much proof is necessary to establish causation).
299. See discussion supra Part IV.A-D.
300. See Cedillo v. Sec'y of HHS, No. 98-916V, 2009 WL 331968, at *134 (Fed. Cl. Feb. 12,
2009).
301. See e.g., Moberly ex rel. Moberly v. Sec'y of HHS, 592 F.3d 1315, 1321-23 (Fed. Cir.
2010). Moberly is a 2010 case that provided a generous discussion of Althen, but no reference to
Althen's "close call" direction. Id.
302. Golkiewicz, supra note 100.
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of "close calls" may be further supported by the creation of more rules
concerning the sufficiency of evidence.
2. "Close Calls" Versus the Preponderance Standard
In addition to defining a "close call," the Federal Circuit must
clarify how the term is to be reconciled with the preponderance
standard.303 This is because the dichotomy between the two standards
presents a further conflict for special masters. The special masters are
simultaneously directed by statute to weigh the evidence by the
preponderance standard, while the Federal Circuit dictated that "close
calls" are to be resolved in favor of the petitioner.3 0 Althen determined
that the preponderance standard referred to by the Act was one of
"simple preponderance, of 'more probable than not' causation."30 s
However, other precedent interpreting the preponderance standard has
determined that the petitioner's burden is met when his evidence
demonstrates by "fifty percent and a feather" that the vaccine caused his
injury.306 Thus the preponderance standard, by its very nature, would
seem to supersede any "close calls."
Interestingly, Pafford v. Secretary of Health andHuman Services3 07
noted "[t]he Court has painstakingly looked for the feather in Petitioner's
argument that would tip the scales past the fifty percent threshold." 08
The Pafford decision was decided one year prior to Althen, meaning the
"close call" principle had yet to be articulated. 3 09 Nonetheless, Paffordis
important because it implies that there might be a relatively
straightforward way to square "close calls" and the preponderance
standard.o It appears feasible that the Federal Circuit could establish a
rule whereby once a special master identifies a "close call," he is to
303. The statutory language of the Vaccine Act and Federal Circuit precedent confirm that the
traditional tort preponderance of the evidence standard is to be applied in vaccine cases. 42 U.S.C.
§ 300aa-13(a)(1) (2006) (specifying that compensation shall be awarded to petitioners who
demonstrate by a preponderance of the evidence that the vaccine caused their injury and that there is
not a preponderance of the evidence that the injury is due to factors unrelated to the vaccine); see
also De Bazan v. Sec'y of HHS, 539 F.3d 1347, 1351-52 (Fed. Cir. 2008); Capizzano v. Sec'y of
HHS, 440 F.3d 1317, 1320 (Fed. Cir. 2006); Pafford v. Sec'y of HHS, 451 F.3d 1352, 1365 (Fed.
Cir. 2006); Althen v. Sec'y of HHS, 418 F.3d 1274, 1279 (Fed. Cir. 2005).
304. Althen, 418 F.3d at 1280.
305. Id. at 1279.
306. See Pafford v. Sec'y of HHS, No. 01-0165V, 2004 WL 1717359, at *4 (Fed. Cl. July 16,
2004) (indicating that the preponderance test is one in which the petitioner must show by "at least
fifty percent and a feather" that the vaccine caused his injuries).
307. 2004 WL 1717359 (Fed. Cl. July 16, 2004).
308. Id. at *9.
309. Althen, decided in 2005, was the first Federal Circuit decision to specifically use the
"close call" language. Althen, 418 F.3d at 1280.
310. Pafford,2004 WL 1717359, at *9.

http://scholarlycommons.law.hofstra.edu/hlr/vol39/iss3/6

36

Binski: Balancing Policy Tensions of the Vaccine Act in Light of the Omni

2011]

BALANCING POLICY TENSIONS OF THE VACCINE ACT

719

carefully consider all evidence that might facilitate a finding in favor of
the petitioner. In this regard, both the "close call" directive and the
preponderance standard are satisfied.
B. Prognosis:Efficiency andEase
Althen's line regarding "close calls" could actually prove to be quite
instrumental in the attempt to strike a balance between the competing
policies that burden special masters. However, a better understanding of
"close calls" will require some effort by the Federal Circuit to clarify the
concept. The Federal Circuit must revisit the Vaccine Act and carefully
consider the fundamental values underlying its inception. It is evident
from the legislative history that while Congress had an interest in
promoting the use of vaccines,3 1 a primary objective of the Act was to
compensate those who had been injured by vaccines.3 12 As discussed
earlier in this Note, the decisions of special masters are afforded great
deference by reviewing courts.3 13 Thus, the Federal Circuit must
structure more rules that will give guidance to special masters as to how
to correctly reach their findings of fact and conclusions of law.
There is a possibility that a clarification of "close calls" will not
provide enough guidance to the special masters to strike any meaningful
balance. However, this option is still the best starting point because it is
considerably quicker and easier than amending the Vaccine Act. Time is
certainly of the essence to the five thousand petitioners in the OAP
whose claims await judgment.314 An effort to reform the Vaccine Act
could tack on months or years before these cases are decided. Finally,
revision of the Vaccine Act is simply not necessary. Congress structured
the Act and then deferred to the Federal Circuit to interpret the
legislative intent and implement it in the form of revised rules." Thus,
all that is necessary for the future is additional interpretation and more
concrete rules from the Federal Circuit to remedy the deficiency in
guidance that currently encumbers special masters.

311. See H.R. REP. No. 99-908, at 5 (1986), reprinted in 1986 U.S.C.C.A.N. 6344, 6346
("[T]he Federal government has an interest in the development, distribution, and use of vaccines,
including those designed to prevent non-childhood diseases.").
312. See discussion supraPart III.
313. See discussion supraPart II.C.3.
314. Medical and non-medical costs for a person with extreme autism can accumulate up to
$72,000 a year, and treatment for people with mild to moderate autism can cost upwards of $67,000
per year. Walecia Konrad, Dealing with the FinancialBurden ofAutism, N.Y. TIMES, Jan. 23, 2010,
at B6.
315. See supra Part 1I.C.1, 3.
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CONCLUSION

The use of vaccines has protected millions of people from lifethreatening diseases and is undoubtedly one of the most significant
public health achievements in history. However, vaccines carry certain
unavoidable risks, and it is inevitable that some individuals will suffer a
serious injury as the result of a vaccination. In recognizing both the risks
and benefits of vaccines, Congress envisioned a system that would
simultaneously ensure the continued supply of vaccines and compensate
those who had been injured. Congress also recognized an interest in
upholding the use of vaccines and mandated vaccination schedules for
all children wishing to enroll in schools and daycare centers. As a result,
the public health in general has dramatically increased and several oncedeadly diseases have been eradicated or are on a significant decline.
The fact that the vaccine supply has remained stable and that
several people have been compensated for injures is a testament to the
many successes of the Vaccine Injury Compensation Program. However,
the system has been frustrated in recent years by the overwhelming
increase in petitions asserting a link between vaccines and ASD. The
vaccine-ASD controversy became so powerful that it eventually
influenced the creation of the OAP, a unique procedure to assist the
Vaccine Court in handling the large volume of these claims.
Cedillo, a test case in the OAP, failed to establish the necessary link
between vaccines and autism.3 16 However, Cedillo is important for other
reasons because it highlights the existence of incompatible policy
concerns that may influence the outcome of many of the OAP cases.
The policy tensions that surround the VICP have remained unresolved
and now beleaguer the special masters during the process of fact-finding.
The Cedillo decision was undeniably a tremendous disappointment
for the approximately five thousand petitioners remaining in the OAP.318
316. See supra Part II.E.2, 4.
317. See supra PartIV.
318. Cedillo v. Secretary of Health and Human Services Highlights Failure of the Vaccine
Injury CompensationProgram, ELIZABETH BIRT CTR FOR AUTISM L. & ADVOCACY (Aug. 30, 2010,
16:12 PM), http://www.ebcala.org/areas-of-law/vaccine-law/cedillo-vs-secretary-of-health-andhuman-services-highlights-failure-of-the-vaccine-injury-compensation-program (quoting the mother
of an OAP petitioner, "[t]hese are government lawyers, representing a government agency,
presenting government-funded science to government judges, with no jury and no normal rules of
evidence ... [w]here's the justice in that?"'). The Birt Center asserts that the Court failed to do
justice to Michelle Cedillo and the other OAP petitioners and that the case emphasized the overall
failure of the VICP. Id. Mary Holland, Executive Director of the Birt Center, stated that
."[i]mpartiality is the bedrock of any judicial system, and the VICP failed to exhibit it in the
Omnibus Autism Proceeding."' Id; see also Avery Johnson, US. Court Rejects Vaccine Connection
to Autism: Rulings Deny Notion That Mercury Preservative Interacts With Other Childhood
Inoculations to Cause the Disorder, WALL ST. J., Feb. 13, 2009, at A3 (quoting the mother of
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Nevertheless, Cedillo does not end the vaccine-autism controversy, and
it will not deter the pending petitioners or new petitioners who believe in
a causal link from attempting to receive compensation.319 Regardless of
the Court's denial of a link between vaccines and ASD, the policy
tensions that have fallen to the special masters must be acknowledged
and resolved to ensure that future OAP claims are decided correctly and
that the intent of the Vaccine Act is upheld.
Laura A. Binski*

another VICP petitioner, "'I listened to the test case and I honestly felt it was a strong case ... [i]t
puts us at an enormous disadvantage when the first three test cases are found for the Department of
Health and Human Services. . . [w]hen does anecdotal evidence become enough?").
319. See Gardiner Harris, Opening Statements in Case on Autism and Vaccinations, N.Y.
TIMES, June 12, 2007, at A2 1. ("Many parents who claim that vaccines gave their children autism
are deeply suspicious of what they see as the government's role in their children's illness. Most have
dismissed the many government-sponsored studies and panels that found no link between
vaccination and autism.").
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